Specific activity of leucocyte alkaline phosphatase in relation to thyroid status of clinical thyroid patients. by Cheung, Moon-Wo. & Chinese University of Hong Kong Graduate School. Division of Pathological Sciences.
Specific Activity of Leucocyte Alkaline Phosphatase 
in relation to thyroid status of 
clinical thyroid patients 
CHEUNG M o o n 挪 ； 
f / … ‘ \ 
A Thesis �,丨 � 
I 广 ： ‘ 奶 n “ d II I I 
submitted in c o n f b r m i ^ ^ t h the degree of 
‘ ‘ i .. 
Master of Philosophy 
X..-
Department of Chemical Pathology 
Division of Pathological Science 
Graduate School 
The Chinese University of Hong Kong 
JULY, 1994 
- - - •• — 
7 ‘ 





List of Abbreviation 
Chapter 1 Introduction 
Thyroid diseases - a background 
Thyroid function tests and their significance 
Cellular actions of thyroid hormones 
Thyroid hormone action at the molecular hormones 
Chapter 2 Aims of the project 
Introduction 
Subcellular localization of human neutrophil alkaline 
phosphatase 
�‘ Prospect of a quantitative assay of leucocyte alkaline 
phosphatase 
Chapter 3 Subjects and methods 
Specimen preparation 
Assay for total protein 
Assay for leucocyte alkaline phosphatase activity 
Other Assays 
Chapter 4 Results 
Relationship between LAP score and specific activity 
of Leucocytic Alkaline Phosphatase(SA-LALP). 
— Diagnosis of hypothyroidism in relation to TSH and FT4. 
” Relation between SA-LALP, TSH and FT4 
Relation between FT3 and other results 
Relationship between SA-LALP and TSH 
ROC plot, distribution of SA-LALP and LAP score values 
Chapter 5 Discussion 
Chapter 6 Conclusion 
• •‘ 
. . . 
2 
‘ • . ‘ . 
• k 
Appendix 
I Summary of patient particulars 
II Summary of test results of patients 
i n Consent form for participate subjects 
IV References 
\ 
• • — . - . - 、 . � , — - - -• — • ------
Acknowledgement 
I would like to express my deepest appreciation and sincere thanks to Professor 
J.R.L. Masarei for his advice, inspiring ideas, patience, and encourgement offered to 
me during my course of study. I am also indebted to Dr AYW Chan for his invaluable 
advice and technical support, and Dr ACC Shek for his help on getting patient 
samples and advice on clinical aspect of thyroid disorders. 
I 
Finally, my thanks are also due to staffs of Department of Chemical Pathology, The 
Chinese University of Hong Kong and Chemical Pathology Laboratory, Clinical 




The effect of varied thyroid status of thyroid patients and normal subjects on specific 
activity of alkaline phosphatase within human leucocyte was studied. Thyroid function 
tests including sTSH，FT3 and FT4 were performed in parallel with Specific Activity 
of Leucocyte Alkaline Phosphatase(SA-LALP) as well as Leucocyte Alkaline 
Phosphatase(LAP) score for those subjects. A significant negative correlation exists 
between sTSH level and SA-LALP as well as LAP score for values of sTSH indicative 
of hypothyroid state. This is consistent with findings with that of Refetoff and 
coworkers(1989) showing the relationship between LAP score and Free Thyroxine 
Index(FTI). The quantitative method for measuring SA-LALP, developed and 
employed in this study showed superiority over LAP score(semi-quantitative 
approach) in showing hypothyroid status indicated by sTSH results, as can be seen 
from ROC plot. Currently no reliable cellular(not serum) marker has been available for 
detecting hypothyroid status. SA-LALP has the potential for serving as such an entity 
provided that the technique involved be further polished and more specifically, specific 
activity for neutrophil rather than total leucocyte population be measured, since 
alkaline phosphatase activity had been found to locate predominantly in neutrophils 
alone. 
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THYROID DISEASES - A BACKGROUND 
THTROID GLAND 
I 
The thyroid gland is a bibbed structure overlying the trachea, and normally weighs 
about 20g. The gland develops from an outgrowth of the inferior aspect of the 
primitive foregut. It is composed of cells forming follicles which enclosed a 
homogeneous substance, the thyroid 'colloid', consisting of a protein of high 
molecular weight, thyroglobulin. Interspersed between the follicles are the 
parafollicular, cells that are one of the sites of formation of the hormone calcitonin, the 
follicles and the enclosed colloid are concerned with the synthesis of the two thyroid 
hormones thyroxine (T4) and triiodothyronine (T3). These are both formed by the 
iodination of tyrosine, with the formation of monoiodothyronine (MIT) and 
diiodothyronine (DIT) as intermediates. The thyroid hormones circulate in the blood 
largely (over 99.9 per cent) in combination with certain plasma proteins. It is 
however, the very small proportion that circulates in the free or unbound state that 
determines the thyroid state of the individual. 
A proportion of thyroxine is deiodinated to triiodothyronine in the peripheral tissues, 
and indeed this process is largely responsible for the biological activity of thyroid 
hormones. An alternative product of peripheral deiodination of thyroxine is reverse 
triiodothyronine which is biologically inactive. 
. \ 
The functional activity of the gland is controlled by the thyroid stimulating hormone 
(TSH) secreted by the pituitary, the release of which is stimulated by TSH releasing 
, hormone (TRH) manufactured by cells of the hypothalamus. An increase in the level 




suppressing the secretion ofTRH and TSH, thereby attempting to maintain a constant 
level of circulating hormone. 
The activities of the thyroid hormones affect most tissues. These include control of 
oxygen consumption and of heat production, and a role in promoting growth and 
development. The action of thyroxine is slow, with a peak effect 9 days after a single 
dose, while triiodothyronine acts more rapidly, probably because it is less strongly 




RELATIVE BIOLOGICAL SIGNTFICANCE OF THYROID HORMONES 
T4 normally is the most abundant iodothyronine in thyroglobuUn, being about 10 to 
20 times more abundant than T3, 20 to 100 times more abundant than rT3 [1,2,3], 16 
I 
to 4500 times more abundant than thyronine (To) [4] and more than 1000 times more 
abundant than any other Tq derivative [5]. In semm，T4 is bound to three proteins, 
which are, in order of their affinity for T4, thyroxine-binding globulin (TBG), 
thyroxine-binding prealbumin (TBPA)，and albumin [6]. The extent of overall binding 
’is great, so that the serum free T4 concentration is less than 0.1% of the total T4 
concentration. Like T4, T3 in the circulation is largely (>99.5%) bound to TBG, 
TBPA, and albumin, but its affinity for these proteins is less than that of T4. The 
compound 3,3',5'-triiodothyronine is commonly known as reverse T3, since the 
arrangement of its three iodine atoms is contrary to that of T3: there is only one 
iodine substitution on the inner, tyrosyl ring of the thyronine nucleus and two iodine 
substitutions on the outer, phenolic ring. Like T4 and T3, rT3 in serum is almost 
completely bound to proteins, the free fraction being about 0.3%, a value simlar to 
that for T3 [7]. 
Because one third to one half of the T4 that is secreted is converted to T3, and 
because the calorigenic activity of T3 is two to four times greater than that of T4, 
conversion to T3 is an important step in the action of T4. Serum T3 levels change 
little between doses in hypothyroid patients treated once daily with T4, while those in 
patients treated with T3 fluctuate widel). Thus the production of T4 and its constant 
source of T3 provide a more constant level of T3 than might be the case if T3 were 
produced only by the thyroid. Furthermore, the fact of extrathyroidal T3 production 
provides an additional level at which it may be regulated. 
Some evidence suggests that T4 may itself be capable of hormonal action. For • . . • ... 
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example, some clinically hypothyroid patients have elevated serum TSH, subnormal 
total, and free T4’ but normal total and free T3 concentrations [8], These data suggest 
that in the absence of a normal level of T4，a normal level of T3 may not be adequate 
to sustain the euthyroid state and thus T4 may have some hormonal activity. Studies 
I 
of hypothyroid patients treated with replacement doses of T3 [9], who therefore have 
normal serum TSH levels, also provide evidence that supports a hormonal role for T4. 
Serum T3 levels in such patients given T3 once daily range from normal to four times 
normal at various times in the day. The mean serum T3 concentration, calculated by 
integration of the curve of serum concentration against time, is about twice normal, as 
is the estimated daily turnover of T3 [10]. Serum T3 concentrations may have to be 
maintained two to three times normal to normalize serum TSH concentrations in 
hypothyroid patients [11]. These findings suggest that high levels of serum T3 maybe 
needed to maintain euthyroidism and to normalize serum TSH in hypothyroidism 
because serum T4 is low. 
In one attempt to estimate the relative contributions of T4 and T3 to thyroid hormone 
action [12], it was noted that T4 by itself or by conversion to T3 may provide as 
much as 85% of the overall biologic effect of thyroid hormones; about 50% of the 
effect was considered to be by way of conversion of T4 to T3 and the remaining 35% 
to T4 itself. T3 was estimated to be responsible for about 65% of the overall thyroid 
hormone effects. T3 originating from thyroidal secretion appeared to contribute only 
15% or less of the overall effect. The apparently conflicting data that T3 accounts for 
the overall effects of thyroid hormones, on one hand, and that T4 has significant 
hormonal action in several situations, on the other hand may be reconciled by the 
consideration that T3 is the predominant but not unique mediator of biologic activity. 
z The conversions of T4 to T3 and rT3 are probably two physiologically regulated 
phenomena similar to those proposed for vitamin D3. DeLuca [13] and coworkers 
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have described two parallel enzyme systems in the kidney that lead to the conversion 
of 25-hydroxyvitamin D3(25-OH-D3) to either l,25(OH)2-D3, which has 
considerable activity, or 24,25-(OH)2-D3, which has little activity. When production 
of 1，25(0H)2-D3 is diminished, production of 24,25-(OH)2-D3 usually is increased. 
I 
The data on relative turnover rates of various iodothyronines and sources of rT3 [14] 
in adults with serum low T3 and high rT3 concentrations are still limited [15]. Studies 
in fetal sheep have demonstrated an increase in production rate of T4 and, in relation 
to it, a decreased production rate of T3 and a normal (not increased) production rate 
of rT3. These results raise the possibility that in addition to T3 and rT3, there may be 
yet another pathway of metabolism of T4 in the fetus [16]. The situation appears to 
be similar, at least qualitatively, in adults with various nonthyroidal disorders in whom 







C h a p 3 
TPVT^OTOXTCOSIS 
The term thyrotoxicosis is generally understood in terms of the catalogue of clinical 
and experimental observations, which has been accumulated over the past century 
describing the clinical, physiological and biochemical changes due to thyroid hormone 
excess. 
I 
The most helpful symptoms for the diagnosis of hyperthyroidism include those of 
heat intolerance, excessive sweating, increased appetite and weight loss， 
"nervousness", tiredness and palpitations. The most helpful signs include those of 
goitre (diffuse with br.it in Graves,)，exophthalmos (Graves'), Ud retraction, Ud lag, 
hot moist palms, tremor and excessive movements，tachycardia or atrial fibrillation 
(AP) These symptoms and signs are highly nonspecfic and may be present in normal 
physiological conditions and some other disorders. However, if they occur in groups， 
the diagnosis of hyperthyroidism is highly indicated. Many of the above features are 
attnbutable to the raised basal metabolic rate which is, in turn, due to the effects of 
excessive amounts of thyroid h o麵 n e on the tissues: The serum levels of T3 and less 
often T4 are.raised and pituitary TSH secretion is inhibited. The common chmcal 
. f o r m of hype r thy ro id i sm. Graves' disease, is due to a thyroid-stimulating auto-
autibody which reacts with the TSH receptors on the thyroid cell membrane. In such 
cases there is usually prominence of the eyes (exophthalmos) apparently caused by a 
second auto-antibody which reacts with orbital muscle. Less often autonomous 
hyperfunctioning thyroid tumour-like nodules lead to thyrotoxicosis. 




(1) Graves, disease 
The most common is characterised by difilise thyroid hyperplasia due to the presence 
I 
of an inappropriate thyroid-stimulating antibody in the blood. 
The disease is most common in females, particularly during the reproductive period 
(F:M ratio二7:1 ； peak incidence at age 30 -50) and sometimes runs in families, 
especially in those in which there is an abnormally high incidence of organ-specific 
auto- immune diseases, e.g. Hashimoto's disease and pernicious anaemia. 
Graves' disease is due to an auto-antibody which reacts with the thyroid epithelial cell 
surface receptor for TSH [17]. This thyroid-stimulating antibody is detectable in the 
blood of most untreated patients by an in vitro test in which the binding of labelled 
TSH by human thyroid cell membrane preparations is competitively inhibited by the 
patient's serum. In some cases, the thyroid-stimulating antibody can cross-react with 
mouse or guinea-pig thyroid epithelium and causes thyroid stimulation in these 
animals in vivo. In fact this is how the antibody (originally termed long-acting thyroid 
stimulator or LATS was first demonstrated). Thyroid-stimulating antibody has been 
shown to be quite distinct from TSH. 
The auto-immune nature of Graves' disease is supported also by the frequent presence 
of focal auto-immune thyroiditis and other organ-specific auto-immune diseases, such 
as pernicious anaemia. Thyroid-stimulating antibody explains the failure to 
demonstrate TSH in the serum of patients with Graves' disease, and the failure of 
administered T3 to suppress thyroid activity in these patients _ findings indicating that 
, pituitary TSH production in Graves' disease is fuUy suppressed by the inappropriately 
high blood levels of thyroid hormone. Further support is obtained from the 
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correlation between the presence of maternal thyroid- stimulating antibody and the 
occurrence of temporary thyrotoxicosis in the neonate. Thyroid-stimulating antibody 
which reacts specifically with preparations of orbital muscle has been demonstrated in 
the serum of most patients with exophthalmos and may well be responsible for this 
t 
abnormality [18'. 
(2) Toxic adenoma . 
Approximately 1% of thyroid adenomas give rise to hyperthyroidism, usually mild and 
not accompanied by exophthalmos or thyroid- stimulating antibody in the serum. 
Because of the autonomous nature of the growth, this cannot be suppressed by T3. 
The remainder of the gland does not concentrate iodine since the hormone produced 
by the tumour results in diminished secretion of TSH by the pituitary. This disorder 
occurs mainly in elderly women. 
(3) Toxic nodular goitre 
This disorder usually affects patients over 50 years of age who have had nontoxic 
goitre—for many years. The thyrotoxicosis which subsequently develops is usually mild 
as judged by thyroid hormone levels in the blood. Cardiac arrhythmias and failure may 
cause the presenting symptoms. Exophthalmos is uncommon. Half of the patients 
have T3- toxicosis (normal T4). 
z A thyroid scan is helpful for diagnosis of toxic adenoma and toxic nodular goitre. 
Scanning the neck following administration of radio-iodine shows marked radio-
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iodine uptake by toxic adenoma. For Graves' disease, scanning shows diffijse uptake. 
The above 3 causes account for over 90% of cases. Rarer causes include subacute 
thyroiditis : viral (de Quervain's - painful ) and lymphocytic (painless); exogenous 
» 
iodide (eg. cough mixture abuse), and factitious hyperthyroidism (ie. oral T4 abuse). 
A pituitary cause is extremely rare. 
Subacute thyroiditis follows a course of transient hyperthyroidism (inflammation, 
causing release of colloid), transient hypothyroidism (impaired iodine uptake), then 
restoration to the euthyroid state over a period of a few months. In both subacute 
thyroiditis and factitious hyperthyroidism .the uptake of radioactive iodine is reduced, 
distinguishing them from Graves' and toxic nodular goitre (where it is increased in the 
nodule). 
There are three types of treatment for thyrotoxocosis. 
1. Drug therapy: 
A variety of drugs inhibit the synthesis of thyroid hormones. The drugs most 
commonly used for the medical treatment of thyrotoxicosis are the thionamides, 
which block the stages of iodination of tyrosine and the coupling of iodinated tyrosine 
to form triiodothyronine and thyroxine. 
2. Surgery: �‘ 
Partial thyroidectomy is performed once the patient is euthyroid on medical treatment. 
The immediate results are good in 90 per cent of patients and the mortality of the 
operation is low. On follow-up, thyrotoxicosis recurs in 5 to 10 percent of patients. 
, The risk of subsequent hypothyroidism is variable and the reported incidence ranges 
from 5 to 40 percent. 
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3. Radio-iodine Treatment: 
This is a very convenient form of treatment as it consists solely of a drink of water 
containing radioactive iodine (usually 131!) in a dose estimated to be adequate to 
restore normal thyroid function. About two-thirds of patients so treated become 






Hypothyroidism is a conditon of deficient thyroid hormone secretion. Hypofunction of 
the thyroid is usually the result of a primary thyroid disorder (primary 
hypothyroidism), although it is sometimes caused by reduced TSH production by the 
pituitary (secondary hypothyroidism). Primary hypothyroidism may occur for the 
following reasons: 
1. Failure of development of the thyroid: This results in hypothyroidism at birth or in 
early infancy (cretinism). 
2. Removal at operation: destruction by radio-iodine therapy: or replacement of the 
normal gland by infiltrative lesions. 
3. Iodine deficiency: This occurs particularly in mountainous areas, as seafish and 
edible seaweeds are rich sources of iodine. The incidence of iodine deficiency in such 
areas is markedly reduced by adding iodide to table salt or drinking water. 
4. Autoimmune thyroiditis (Hashimoto's disease or Hashimoto's thyroiditis): 
Circulating antibodies to different constituents of thyroid tissue can be demonstrated 
in patient's serum, and are of value diagnostically. An association between this 
condition and other 'organ specific丨 autoimmune diseases, such as pernicious anaemia, 
is found in patients with autoimmune thyroiditis and their close relatives. 
5. Congenital enzyme defects of thyroid hormone synthesis: These abnormalities are 
usually familial and inherited as recessive characteristics. Defects involving all the 
stages of thyroid hormone synthesis have been described and one form is associated 




disease in childhood. 
6. Drug induced: Hypothyroidism may be caused by the antithyroid drugs and other 
compounds that inhibit thyroid hormone synthesis such as iodine (used in many cough 
J 
medicines). Natural goitrogens also exist and may occasionally produce 
hypothyroidism. 
Treatment of hypothyroidism is with thyroxine. A usual adult replacement dose is 
0.15 or 0.2 mg per day which, in view of its long duration of action, need only be 
given once daily. In elderly subjects and patients with long-standing hypothyroidism, 
there is a risk of precipitating ischaemic heart disease on starting treatment. Low 
doses, such as 0.025 mg daily are commenced, which are then gradually increased 
every 2 or 3 weeks so long as there are no side effects. When there is need for a quick 
response, as in myxoedema coma, the rapidly acting thyroid hormone triiodothyronine 






A variety of nonthyroidal illnesses are capable of producing alterations in serum 
thyroid hormone concentrations in people who have no apparent intrinsic thyroid 
disease. Most commonly these assume the form of � a low triiodothyronine (T3) 
state, in which serum total and free T3 concentrations are low but serum thyroxine 
(T4) and thyroid-stimulating hormone (TSH) values remain within the normal range, 
or (2) a low T3-T4 state, which occurs in more severely ill patients and-is 
characterized by low serum T4 and low T3 concentrations. 
I 
The nonthyroidal illnesses that cause these changes vary widely，from trauma, sepsis, 
malignancy and metabolic disorders to febrile illness and undernutrition. In short, the 
chanaes occur in virtually all illnesses [19,20], however, the changes in thyroid 
O -i 
indexes in nonthyroidal illness are usually not an isolated endocrine event but are 
associated with an array of other systemic hormonal responses. For example, varying 
decrees of reduction in circulating insulin-like growth factors (IGF) and in 
gonadotropin and sex hormone levels, as well as increases in serum ACTH and 
Cortisol, frequently accompany the changes in thyroid function in patients with 
nonthyroidal illness [21,22,23,24]. It is likely therefore, that this spectrum of 
endocrine responses is promoted by factors that coordinate host reactions to illness 
and injury. 
Factors that appear to regulate these processes have been identified and termed 
cytokines. Cytokines are polypeptide humoral agents, mainly produced by cells of the 
immune system (macrophages’ monocytes, and lymphocytes), that are capable of 
inciting a multiplicity of local as well as systemic responses after injury and during 
illness [25]. Three general classes of cytokines are presently recognized: interleukins, 
interferons, and tumour necrosis factor. When experimentally administered to an 
z 
.animal or man, they produce virtually all the characteristic clinical features of illness, 
53 
Chap 3 
including fever and leukocyte responses, as well as endocrine alterations mentioned. 
A substantial depression of serum total and free T3 concentrations in association with 
normal or near-normal serum TSH and total and free T4 concentrations is the most 
f 
common thyroid response to nonthyroidal illness. This pattern is usually referred to as 
the low T3 state. In two studies, more than half of adult patients admitted to a 
medical service had this pattern of thyroid test results [26,27]. The magnitude of the 
decline in serum T3 concentrations varies widely and is generally related to the 
• severity of the illness. In certain instances, such as patients with cirrhosis or acquired 
immunodeficiency syndrome, this fall in serum T3 values may additionally serve as an 
important prognostic indicator of clinical outcome [28 • 
An impairment in peripheral (extrathyroidal) tissue conversion of T4 to T3 is believed 
to be responsible for the low serum T3 concentrations [29], although direct evidence 
documenting a decrease in 5丨-deiodinase enzyme activity has not been forthcoming. 
Normally, about 80% of circulating T3 is produced in peripheral tissue by 5'-
deiodination of T4. The remainder is secreted by the thyroid gland [30]. 
The use of more sensitive serum TSH assays has allowed recognition of subnormal 
serum TSH concentrations, which was not possible previously. It is unusual for semm 
TSH values in nonthyroidal illness to be below 0.01 mU/L, the level characteristically 
associated with clinically overt thyrotoxicosis [31]. Furthermore, in most patients with 
subnormal semm TSH levels, the level容 normalized within 2 to 5 days, underscoring 
the transient character of dysregulation of TSH secretion. Although the levels also 
rapidly normalized in most patients with elevated TSH levels, some patients had 





THYROID FUNCTION TESTS AND THEIR SIGNIFICANCE 
Since each test has inherent limitations, and no single procedure is diagnostically 
adequate for the entire spectrum of possible thyroid abnormalities, those tests which 
are most useful in evaluating thyroid status and for' clinical management of thyroid 
patients will be discussed. 
i 
M g A L METABOLIC RATE (BME) 
The BMR has a long history in the evaluation of thyroid function. It measures the 
oxygen consumption under basal conditions by allowing the person to breathe into a 
closed system, under presumably basal conditions of overnight fast and rest from 
mental and physical exertion. Since the equipment for the measurement of BMR may 
not be readily available, it can be estimated from the oxygen consumed over a timed 
interval by analysis of samples of expired air [33]. The test indirectly measures 
metabolic energy expenditure or heat production. Results are expressed as the 
percentage of deviation from normal-after appropriate corrections have been made for 
» 
age, sex, and body surface area. Low values are suggestive of hypothyroidism, and 
high values reflect thyrotoxicosis. The various nonthyroidal illnesses and other factors 
affecting the BMR, including technical errors, have been reviewed [34]. 
Although this test is no longer a—part of the routine diagnostic armamentarium, it is 
still useful in research and on rare occasions in clinical practice. 
53 
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IODINE CONTENT ESTIMATION TECHNIQUES 
• 
The determination of protein-bound iodine (FBI) has passed from routine use. Under 
good conditions the test can provide an accurate index of circulating thyronines: 
however, it is especially prone to interference by other iodine compounds (both 
inorganic ions and organic agents such as x-ray contrast media). One contaminated 
sample in a batch can affect other samples and apparatus, and cause trouble for weeks 
I 
by contamination of workrooms, furnaces, etc. Both manual and automated methods 
are tedious and require considerable time and expertise. The interpretation of the test 
is reviewed in some detail by Acland (1971) [35]. 
The serum sample is digested by acid and heat, and the minute amounts of iodine 
released are estimated by their catalytic effect on the reduction of yellow eerie ions to 
colorlesss cerous ions by arsenious acid. 
THYROID-STIMULATING TMMRRNOGLQBULINS FTSI) 
A large number of names have been given to tests that measure abnormal gamma-
globulins present in the serum of some patients with autoimmune thyroid disease, in 
particular, Graves' disease. 
r- _ - _ 
> 
The interaction of these immunoglobulins with thyroid follicular cells usually results in 
a global stimulation of thyroid gland activity and only rarely causes inhibition. The 
earliest assays employed various modifications of the McKenzie mouse bioassay [36-
38]. The abnormal gamma-globulin with TSH-like biological properties has relatively 
longer in vivo activity - hence its name, long-acting thyroid stimulator (LATS). The 
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assay measures the LATS induced release of thyroid gland prelabeled with 
radioiodide. 
Attempts to improve the ability to detect thyroid-stimulating antibodies (TSAb) in 
autoimmune thyroid disease have led to the development of several in vitro assays 
using animal as well as human thyroid tissue. In a cytological assay, the ability of 
human serum to stimulate endocytosis in fresh human thyroid tissue is measured by 
the use of such a technique. Human thyroid stimulator (HTS) activity has been 
I 
demonstrated in seurm samples from patients with Graves' disease that were devoid of 
LATS activity measured by the standard mouse bioassay [39]. TSAb can be detected 
by measuring the accumulation of cyclic cAMP or the stimulation of adenylate cyclase 
activity in human thyroid cell cultures and thyroid plasma membranes, respectively 
[40]. 
Techniques used currently, which may be collectively termed radioreceptor assays, are 
based on the competition of the abnormal immunoglobulins and TSH for a common 
receptor-binding site on thyroid cells. The test is akin in principle to the radioligand 
assays, in which a natural membrane receptor takes the place of the binding proteins 
or antibodies. Various sources of TSH receptors are employed, including human 
thyroid cells, their particulate or solubilized membrane, and cell membranes from 
porcine thyroids or from guinea pig fat cells. Since the assays do not directly measure 
thyroid-stimulating activity, the abnormal immunoglobulins determined have been 
一 given a variety of names such as thyroid-binding inhibitory immunoglobulins (TBH) 




TOTAL THYROID HORMONE 
This test is still used widdy, although sTSH has to a large extent replaced it as a first 
I 
line test where equipment and finance are available. 
Naturally occurring, iodide-containing compounds in serum are currently measured "by 
radioimmunoassays (RIA's). Other assays have been developed that are based on the 
principle of the radioligand assay but do not use radioactive material. These assays, 
which use ligand conjugated to an enzyme, are likely to replace currently used RIA's. 
The enzyme-linked ligand competes with the ligand being measured for the same 
binding sites on the antibody. Quantitation is carried out by spectrophotometry of the 
color reaction developed after the addition of the enzyme substrate. Both 
homogeneous (enzyme-multiplied immunoassay technique [EMIT]) and 
heterogeneous (enzyme-linked immunosorbent assay[ELISA]) assays for T4 have 
been developed. In one such assay, T4 is linked to malate dehydrogenase, inhibiting 
the enzyme activity. The enzyme is activated when the T4-enzyme conjugate is bound 
to T4-specific antibody. Active T4-conjugates to other enzymes, such as peroxidase 
and alkaline phosphatase, have also been developed. The assay has been adapted for 
the measurement of T4 in dried blood samples used in mass screening programs for 
neonatal hypothyroidism. 
The hyperestrogenic state of pregnancy knd the administration of estrogen-containing 
compounds are the most common causes of a significant elevation of serum TT4 
levels in euthyroid persons. Serum TT4 is virtually undetectable in the fetus until 
midgestation. Thereafter, it rapidly increases, reaching high-normal adult levels during 
the last trimester. A further acute but transient rise occurs within hours after delivery. 
y 
Values remain above the adult range until the child is six years of age, but subsequent 
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age-related changes are minimal and not a uniform finding. In clinical practice, the 
same normal range of TT4 applies to both sexes and all ages above six years. Plasma 
Total Thyroxine (T4) essentially measures protein-bound T4, levels of which change 
in parallel with TBG concentration, which in turn can be affected by various factors. 
I 
In summary: ' 
Causes of TBG excess Causes of TBG deficiency 
Pregnancy Protein-calorie malnutrition 
Oestrogens("pill") Protein loss (eg nephrotic 
s 
syndrome) 
Hepatitis Chronic liver disease (eg. cirrhosis) 
Drugs (heroin, methadone, High dose corticosteroids 
perphenazine, clofibrate) 
Heredity (rare) Androgens 
Artefact (venous stasis) Heredity (rare) 
i 
Another possible cause of discrepancy between the observed serum TT4 
concentration and the metabolic status of the patient is divergent changes in the serum 
total triiodothyronine (TT3) and TT4 concentrations with alterations in the serum 
T3/T4 ratio. The most common situation is that of elevated TT3 concentration. The 
source of T3 may be endogenous, as in T3 thyrotoxicosis, or exogenous, as during 
ingestion of T3. In the former situation, contrary to the common variety of 
thyrotoxicosis, elevation in the serum TT3 concentration is not accompanied by an 




is predominantly secreted as such rather than arising from the peripheral conversion of 
T4 to T3 [41]. 
Ingestion of pharmacological doses of T3 results in thyrotoxicosis associated with 
I 
severe depression of the semm TT4 concentration. A moderate hypersecretion of T3 
can be associated with euthyroidism and a low serum TT4 concentration. This 
circumstance occcasionaly referred to as T3 euthyroidism, may be more prevalent 
than T3 thyrotoxicosis. ‘ 
Two rare conditions also characteristically occur with a discrepancy between the 
clinical status and the serum concentration of TT4: (1) the syndrome of tissue 
resistance to thyroid hormone action associated with elevated TT4 as well as free T4 
and TT3 levels and clinical hypothyroidism or euthyroidism [42] and (2) the syndrome 
of hypermetabolism in the absence of thyroid dysfunction described by Luft and 
colleagues [43]. The latter is a defect in the maintenance of mitochondrial respiratory 
control and is independent of the serum T4 concentration. 
T3/T4-Uptake Methods 
The important determinant of thyroid status is the unbound fraction of thyroxine 
present in the plasma, since this is related directly to the tissue dose. Before the 
advent of more simple and straight forward techniques for assessing free T3 and T4, 
the standard but tedious dialyzing method was employed, which is highly unsuitable in 
clinical settings. One alternative is to measure the free binding sites available on the 
carrier proteins of the test sera. 
The principle is that triiodothyronine (T3) labeled with 125-1 or 131-1 is added to the 
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test serum, and binds to free carrier sites which are not already occupied by 
nonradioactive T4 and T3. The radioactive T3 which has not been bound is then 
picked up by adding a carrier; originally erythrocytes were used, but later resins were 
introduced and were found to give more reproducible results. T3 was chosen 
originally, since it binds more firmly to the natural carrier sites, and is therefore less 
easily detached from these when the carrier resin is added. The test is usually called 
the T3-resin uptake test (T3U). The T3U test is thus an indirect measure of TBG 
surplus binding capacity (TBG is normally about one third saturated with T4). 
The % radioactive T3 uptake by the resin is inversely related to the number of 
unoccupied T4 bindings, therefore: 
T3U is elevated in hyperthyroidism( increased TBG saturation, therefore fewer empty 
sites ) 
T3U is depressed in euthyroid pregnancy (increased TBG concentration saturation 
unchanged, therefore more empty sites) 
The T4 and T3-uptake values can be combined to give a figure called the Free 
Thyroxine Index ( FTI ). FTI shows a very close correlation with the free dialyzable 
thyroxine levels. It is obtained by multiplying the TT4 and T3-uptake values together. 
It is preferable for each laboratory to obtain its normal FTI range for the particular 
methods used. This can be done simply by analyzing at least 50 normal sera. 
FTI = total T4 x [ T3U(measured) / mean normal T3U : 
A few problems of interpretation occasionally are encountered: These in vitro tests 
are more sensitive in the diagnosis of thyrotoxicosis than of myxedema. (1) If the 
latter condition is suspected clinically, and the FTI is normal or equivocal, the serum 
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TSH level should be estimated. This will be high in myxedema provided pituitary 
function is normal. (2) In patients who are receiving thyroxine replacement therapy 
and are euthyroid, the T4 and FTI tend to be higher than normal. (3) Occasionally an 
obviously thyrotoxic patient is encountered in whom the serum T4 and FTI are 
I 
normal or even low. In such cases a serum T3 level should be obtained. 
FREE THYROID HORMONE CONCENTRATION 
Although changes in serum hormone-binding proteins affect both the total hormone 
concentration and the corresponding fraction circulating free, in the euthyroid person 
the absolute concentration of free hormone remains constant. The concentration of 
free hormone in serum correlates better with the tissue hormone level and the 
metabolic status of the person. 
The traditional method [44] measures the proportion of the TT4 or TT3 that is 
unbound, or free, and thus capable of diffusing through a dialysis membrane, i.e.，the 
dialyzable fraction (DF). To carry out the test, a sample of serum is incubated with a 
tracer amount of labeled T4 or T3. The labeled tracer rapidly equilibrates with the 
respective bound and free endogenous hormones. The sample is then dialyzed against 
buffer at a constant temperature until the concentration of free hormone on either side 
of the dialysis membrane has reached equilibrium. The DF is calculated from the 
proportion of labeled hormone in the dialysate. The contribution from radioiodide 
present as contaminant in the labeled tracer hormone should be eiiminated by careful 
purification and by various techniques of precipitation of the dialyzed hormone. FT4 
and free triiodothyronine (FT3) levels can be measured simultaneously by addition to 
the sample of T4 and T3 labeled with two different radioiodine isotopes. 
Ultrafiltration is a modification of the dialysis technique [45]. 
• • -. - . • - - •• - - • • •‘ 
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With few exceptions, the free hormone concentration is high in thyrotoxicosis, low in 
hypothyroidism, and normal in euthyroidism, even in the presence of changes in TBG 
concentration, provided the patient is in a steady state. On occasion, the concentration 
t 
of FT4 may be outside the normal range in the absence of an apparent abnormality in 
the thyroid hormone-dependent metabolic status. This has been frequently observed in 
association with severe non-thyroidal illness when both high [46,47] and low [48] 
'values have been reported. Marked elevations in both FT4 and FT3 concentrations in 
the absence of hypermetabolism are typical of patients with gereralized resistance to 
thyroid hormone [49]. The FT3 concentration is usually normal or even high in 
hypothyroid persons living in areas of severe endemic iodine deficiency. Their FT4 
levels are, however, normal or low. 
More recently, several one-step and two-step RIAs for FT4 have been developed with 
the intention of achieving a "direct" measurement of FT4. The term "direct" is 
misleading terminology because most of these tests do not measure free hormone 
directly, but rather the measurement is carried out in a single test. 
In the one-step procedure an 125-1 labeled T4 analog that binds to anti-T4 antibody, 
but presumably not to serum proteins, is mixed with serum and competes with 
endogenous FT4 for binding to immobilized, high-affinity anti-T4 antibody. If that T4 
analogue tracer does not react with serum T4-binding proteins, it competes with free 
T4 for antibody binding sites. Binding of that T4 analogue should be inversely 
proportional to the free T4 concentration. In principle, this technique would give a 
reliable free T4 estimate if interaction of the T4 analogue with serum proteins were 
identical in all samples and standards. If the T4 analogue is bound to an abnormal 
, extent, as in familial dysalbuminemic hyperthyroxinemia or with iodothyronine-
binding autoantibodies, the assay result will be spuriously high. IfT4 analogue binding 
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to serum proteins diminished, as in hypoalbuminemia or when albumin is highly 
occupied by nonesterified fatty acids, the assay result will be spuriously low. 
The two-step assay is a sequential RIA in which endogenous semm FT4 is first 
bound to immobilized anti-T4 antibody; the serum which still contains protein-bound 
T4’ is then decanted. 125-1 labeled T4 is added in the second step to saturate the 
remaining antibody sites, and the amount of bound radioactivity is compared with a 
standard curve for FT4. 
In theory, the T4-analog one step assay is an elegant concept, but an absolute 
requirement is that endogenous serum proteins (albumin, prealbumin, TBG, 
iodothyronine antibodies) must not bind the analog. However, several reports have 
demonstrated serum proteins (especially albumin) do indeed bind the T4-analog, 
which results in a significant perturbation of the assay [50,51]. Thus, in case of 
hypoalbumineamia or in case of plasma T4 binding antibodies increase in case of 
autoimmune thyroid disease, intrepretion may be very misleading. There is continued 
development of analog methods because selective albumin-blocking agents, T4-
enzyme analogs, might eliminate interferences by albumin and T4- autoantibody. 
The two step assay is more tedious, has poorer reproducibility and values may be 
elevated in non-thyroidal illness. Most FT4 kits contain anti-T4 antisera which when 
added to serum, extract a quantity of T4 from the endogenous binding proteins that is 
related to the actual FT4 concentrations. It has been found [52] that the results of 
two-step FT4 methods from two sources correlated better with results by equilibrium 
dialysis than with either the analog procedures or with FT4I (free thyroxin index) • 





THYROID STIMULATING HORMONE ' • 一 
In the presence of a normally functioning hypothalamic-pituitary axis, there is an 
inverse correlation between the semm concentration of FT4 and TSH. Changes in the 
serum concentration of TT4 as a result of TBG abnormalities, or because of drugs 
competing with T4 binding to TBG, have no effect on the level of serum TSH. Thus, 
serum TSH levels are always elevated in patients with primary hypothyroidism and are ‘ 
low or undetectable in thyrotoxicosis. TSH concentrations above the upper limit of 
normal have- been observed in the absence of clinical symptoms and signs of 
hypothyroidism and in the presence of semm T4 and T3 levels well within the normal 
range. This condition is most commonly encountered in patients developing 
hypothyroidism due to Hashimoto's thyroiditis or in those with an inability to 
synthesize thyroid hormone because of prior thyroid surgery, radioiodide treatment, 
or severe iodine deficiency. This picture is also commonly seen in the elderly. 
There are two circumstances in which the usual reverse relationship between the 
serum level of TSH and T4 is not maintained in patients with proven primary 
hypothyroidism. Treatment with replacement doses of T4 may normalize or even 
produce serum levels of thyroid hormone above the normal range before the high 
TSH levels have reached the normal range. This is particularly true in patients with 
severe or longstanding primary hypothyroidism, who may require three to six months 
of hormone replacememt before TSH levels are fully suppressed. Conversely, semm 
TSH concentration may remain low or normal for up to five weeks after withdrawal 
of-thyroid hormone replacement, when serum levels of T4 and T3 have already 
declined to values well below the lower range or normal. 
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The traditional measurement of TSH in clinical practice uses one of the RIA 
techniques. A major problem with early TSH RIA's was cross-reactivity with 
gonadotropins ( LH, FSH AND HCG ) sharing with TSH a common alpha-subunit. 
Another uncommon source of error is the presence in the serum sample of 
heterophilic antibodies induced by vaccination with materials contaminated with 
animal serum or endogenous TSH antibodies. 
Since 1984, a number of immunoradiometric and immunoenzymometric assays that 
utilize monoclonal antibodies to TSH have been developed. Conventional traditional 
assay cannot distinguish normal from decreased levels of plasma TSH, and are 
therefore not useful in diagnosis of thyrotoxicosis. New Immunometric assays offer a 
ten fold increase in sensitivity, thus the term "sensitive TSH" assay be used. In this 
technique, labelled antibody binds analyte (TSH) • The whole complex is then 
attached to a solid phase antibody, which binds to analyte at a site other than that with 
labelled antibody. Excess labelled antibody not bound to analyte is washed off. The 
labelled complex is then counted. 
Labels can be : 125-I(IRMA), Chemiluminecent(ICMA), En2yme(IEMA), 
Flourescent(IFMA). 
Glucocorticoids [531, dopamine agonists [54], and phenytoin [55] each exert 
inhibitory effects on TSH and may be -low for the prevailing level of free thyroid 
hormone. Conversely, serum TSH levels may be inappropriately high in the face of 
glucocorticoid deficiency [57]. Amiodarone has recently been shown to interact with 一 
T3 receptors in cultured pituitary cells. This effect may account for the fact that 




CELLULAR ACTIONS OF THYROID HORMONES 
The cellular effects of thyroid hormones are metabolic, including regulation of cell 
respiration, and developmental. Examples of the latter include mammalian central 
I 
nervous system morphogenesis and amphibian metamorphosis. Certain actions of 
thyroid hormones are known to be genomic, that is, dependent on the high-affinity 
interaction of thyroid hormone with specific receptor proteins that regulate gene 
expression in the cell nucleus {94,126]. Some examples of the genomic actions of 
thyroid hormone are the secretion of growth hormone [127] or thyrotropin(TSH) 
[128] by pituitary cells or the synthesis of specific proteins such as malic enzyme by 
liver cells [129]. The mechanisms of the actions of iodothyronines on cell metabolism 
and on organ development are incompletely understood, and may involve extranuclear 
(non-genomic) as well as nuclear components. 
THYROID HORMONE ACTIONS AT THE PLASMA MEMBRANE 
An interaction of thyroid hormone with plasma membrane binding sites has been 
described in a variety of animal and human cells, such as human placenta [130] and rat 
liver [59]. The affinity of the interaction at these sites is sufficiently high and of 
sufficient specificity (eg, L- versus D-iodothyronines) to support biologic roles for the 
sites. Whether these hormone-cell surface protein interactions are involved in specific 
cellular uptake processes, in plasma ^membrane actions of the hormone, or in 
metabolism of thyroid hormone, has not been defined. 
Thyroid hormone can enter cells by diffusion and by specific transport that may 
, interact with plasma membrane sites and affect, at least in vitro, specific enzyme 
activities, such as those associated with glucose uptake [60] or the calcium pump 
53 
Chap 3 
[61]. The evidence supporting endocytosis as a mechanism of entry is based on the 
ability of monodansylcadaverine, an inhibitor of endocytosis, to restrict uptake of 
iodothyronines by a variety of cells or cell lines [61]. Energy dependence has been 
demonstrated by the use of inhibitors of the mitochondrial electron transport system, 
such as antimycin [62]. Some studies have shown hormone transport across the cell 
membrane to be ion dependent (such as Na+-dependent [63]) as well as adenosine 
triphosphate(ATP) dependent, therefore energy dependent. The results showed that it 
can occur by way of a facilitated transport or antiporter mechanism. (Antiporter 
systems are carriers for two substances that move in opposite directions, one vector 
of which is down a concentration gradient.) 
The effect of thyroid hormone on glucose transport has been reproduced in vivo in a 
variety of tissues in rats when 2-deoxyglucose uptake is measured in tissues obtained 
shortly after administration of hormone to the intact animal [64], The in vivo effect 
also is hormone concentration dependent, but at a greater than physiologic doses of 
iodothyronine. It reduces 2-deoxyglucose uptake in heart, diaphragm, and adipose 
tissue. 
Another non-genomic effect of thyroid hormone is its stimulatory effect on membrane 
Ca2+-ATPase activity. Described in vitro in mature non-nucleated human red cells, 
the stimulation by iodothyronines of Ca2+-ATPase activity occurs at 10-11 to 10-10 
mol/L concentrations of L-T4 and L-T3 and requires calmodulin [65]. However, the 
thyroid hormone dose for Ca2+-ATPas�fe activity is greater than physiologic doses of 
thyroid hormone in vivo. Thyroid-hormone, in the context of its ability to modulate 
plasma membrane Ca2+-ATPase activity, is believed to play a role in setting the level 
of basal activity of the enzyme and hence, serving as one of multiple factors 
, determining the resting levels of Ca2+ in hormone-responsive cells, such as striated 
muscle [66] and myocardial membrane [67]. Ca2+.ATP activities are stimulated by 
. - ' • 一 
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physiologic concentrations of T4 and T3. Thus sarcoplasmic reticulum enzyme 
activity is hormone-responsive. It has been postulated that this effect of thyroid 
hormone on the sarcoplasmic reticulum may contribute to the shortened relaxation 
phase of the deep tendon reflexes in patients with thyrotoxicosis (enhanced 
sarcoplasmic reticulum re-uptake of sarcoplasmic, Ca2+). It is also possible that 
iodothyronines may enhance ATP hydrolysis by the Ca2+-ATPase of sarcoplasmic 
reticulum without increasing Ca2+ uptake (decreased ratio of moles Ca2+ transported 
to moles ATP hydrolyzed), an effect that would be thermogenic. 
ACTIONS OF THYROID HORMONE IN CYTOPLASM 
Much evidence exists for the interaction of thyroid hormone with soluble 
(cytoplasmic) proteins in a variety of tissues. The reports of such binding proteins 
antedated the descriptions of nuclear receptors for iodothyronines [68,69]. In contrast 
to the mechanism of steroid action in target cells, thyroid hormone action at the 
nuclear level is not facilitated by cytoplasmic binding proteins for the hormone, and 
indeed the cytoplasmic proteins that bind thyroid hormone can restrict access of the 
latter to the nucleus. 
A lot of cytoplamic (cytosolic) proteins are found to be capable of binding 
iodothyronines [71,72,73]. For example, a cytoplasmic protein (p58) recently 
described by Cheng and coworkers has been identified as a monomer of pyruvate -
kinase, the enzymatic activity of which requires tetrameric structure [76]. T3 
apparently inhibits oligomerization of the p58 monomer, and thus could inhibit 
pyuvate kinase activity in vivo. Inhibition of pyruvate kinase activity in certain cell 
lines can increase adenosine diphosphate (ADP) accumulation content and increase 




thyroid hormone on cellular respiration. Cell fractionation studies involving 
radioiodinated T4 and T3 indicate that up to 50% of extranuclear thyroid hormone is 
localized to cytoplasm [68,75'. 
The evidence that iodothyronines bind to cytoplasmic proteins and affect certain of 
their functions is substantial. Whether such actions represent physiologic effects is less 
certain because supraphysiologic concentrations of the hormones are required and the 
relative potency of hormone analogues is variable. 
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THYROID HORMONE ACTIONS ON MITOCHONDRIA AND CELLULAR 
RESPIRATION 
It had been found that the uptake of oxygen by isolated mitochondria in vitro can be 
enhanced by physiologic concentrations of thyroid 'hormone [77], This indicates that 
the cell nucleus need not be involved in hormone regulation of mitochondrial activity. 
Indeed, T3 is reported to stimulate liver cell respiration when protein synthesis -has 
been blocked with cycloheximide [77]. Radio-autographic electron microscopy has 
localized 15% or more of subcellular labeled T3 in mitochondria [77；. 
There are many sites in the mitochondrion where thyroid hormone might act to 
regulate cell respiration. Some examples of investigations include those of ADP-ATP 
transporter(translocase) [78], mitochondrial phosphate transporter [79], 
intramitochondrial proton transfer [80], content of specific cytochromes in the 
mitochondrial electron transport chain [81], and malic enzyme in cytoplasm [82]. 
However, these contentions have either been denied or not substantiated by other 
findings. 
Although the respiratory effects of thyroid hormone remain incompletely understood, 
it must be emphasized that any cellular process that leads to excessive ATP 
consumption in the cell will result in increased oxygen consumption and oxidative 
phosphorylation. Haber [83] have shown that thyroid hormone increases the 
permeability of plasma membrane Na+’K+-ATPase activity (and ATP consumption) 
and therefore promotes Na+ export. This effect is to be distinguished from the 
nucleus-mediated effect of iodothyronines on Na+，K+-ATPase [83]. 
Finally, insofar as intramitochondrial events are concerned, it was believed several 
decades ago that thyroid hormone uncoupled oxidative phosphorylation, reducing the 
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P/0 ratio (the number of ATPs produced per atom of oxygen consumed when NADH 
is the electron donor). This uncoupling effect is now recognized to be an in vitro 
function of pharmacologic concentrations of thyroid hormone [55], as is the action of 
iodothyronines to disrupt mitochondrial structure through "swelling" [84]. 
I 
MORPHOGENESIS AND THYROID HORMONE . 
The morphogenetic importance of iodothyronines in higher animals is shown in such 
diverse actions as nerve cell development, heart ventricle development, ontogeny of 
the exocrine pancreas, craniofacial morphogenesis, liver development, and lung 
development. The effects of thyroid hormone on central nervous system development, 
including myelination, are recognized to be of particular importance to postnatal 
neurologic and behavioral maturation [85:. 
An interesting finding is that the binding capacity of nuclear receptors for T3, 
expressed per unit of DNA, doubles abruptly at birth in rat brain [86], subsequently 
falling in the adult to the level found in fetus. The central nervous system actions of 
thyroid hormone during fetal development are particularly impressive in terms of 
dendrite formation of specific groups of neurons, such as Purkinje cells and neurons 
of the caudate nucleus. Although these morphologic effects are well described, the 
biochemical changes that underlie them and how the changes are influenced by thyroid 
hormone are not known. 
In addition to these organ-specific morphogenetic effects in the fetus or neonate, 
thyroid hormone influences postnatal somatic growth (length and mass of the 
organism). The mechanisms by which iodothyronines enhance organism growth at 
least in part involve synergist!sm with growth hormone, as shown particularly clearly 
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in thyroidectomized and hypophysectomized rats receiving hormone supplementation 
[87], and also in studies in which growth hormone had little effect on somatic growth 
rates [88]. Development of the bony skeleton in children and animals is accelerated by 
excessive thyroid hormone administration. 
i 
Morphogenesis and somatic growth in higher animals and amphibian metamorphosis 
are highly complex, coordinate processes that must be exquisitely regulated in terms 
of timing and magnitude. These processes appear to rely on the emergence of 
hormone-binding sites in the nuclei of target organ cells. These sites are termed 






THYROID HORMONE ACTION AT THE MOLECULAR LEVEL 
THYROID HORMONE RECEPTORS 
I 
During the 1950s and 60s, thyroid hormone was believed to control metabolic action 
by uncoupling oxidative phosphorylation [89,90], despite observations that oxidative 
phosphorylation in muscle of thyrotoxic humans and animals was normally coupled to 
generation of high-energy phosphate bonds. In 1963, Taka [91] showed that thyroid 
hormone caused prompt changes in mRNA and protein synthesis, thereby shifting 
interest to a nuclear site of action for the hormone, In 1972, Oppenheimer reported 
the presence of thyroid hormone binding substances, putative receptors, in pituitary, 
kidney and liver [92,93], Since that time, the concept that thyroid hormone carries out 
its action through nuclear receptors had dominated research in this field. 
Before the discovery of the relation of c-erb A to T3 receptors, understanding of T3 
nuclear mechanisms depended almost exclusively on studies based on the interaction 
of isotopically labeled T3 with nuclei or nuclear extracts. These studies allowed 
measurements of the specific binding T3 to nuclear receptors, the nuclear T3 binding 
capacity, and the affinity of such receptors for T3 and its analogues. Early 
experiments were carried out in various rat tissues after the intravenous injection of 
tracer amounts of (^^^1)73 together with graded doses of unlabeled T3 [94]. Kinetic 
studies showed rapid rates of equilibration of T3 between plasma and tissue and 
between the cytosolic and nuclear pools [95]. Methods subsequently were developed 
for determining these parameters in incubated nuclei [96] and in nuclear extracts [97'. 
Subcellular fractionation studies showed that the T3 receptors were associated almost 
exclusively with nuclei and were present both in euthyroid and hypothyroid states. 
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Estimation of the molecular weight and the sedimentation constant by standard 
techniques suggests values of about 50kd and 3.5S, respectively [98]. Measurement 
of the affinity of nuclear receptors for T3 using a whole nuclei assay has yielded a 
value of about 1 X lOlOmohl. Scatchard plots show a single class of binding sites. 
Inhibition of the binding of tracer T3 by unlabeled T3 and its analogues reveal a weil-
defmed hierarchy in binding affinity of the analogues [98]: in descending order, 
Triiodothyroacetic acid (triac), T3, T4 and rT3, with diodotyrosine and 
monoiodotyrosine having no capacity to inhibit T3 binding. There appears to be a 
near-perfect relationship between the affinity of these analogues for the receptors and 
their thyromimetic properties when due account is taken of the metabolism and 
distribution in the intact animal or in the cell system under study [99]. The rank order 
of binding of these analogues to receptors derived from different tissues and from 
different vertebrate tissues is indistinguishable, as are the gross physicochemical 
characteristics of the T3 nuclear complexes [100]. 
RELATION OF RECEPTORS TO THE ONCOGENE V-ERBA 
The maximal percentage yields of purified T3 receptors obtained by the application of 
conventional biochemical methods [101] are only 4.2% to 4.9%. Still unclear are the 
structural differences between steroid receptors and T3 receptors, which account for 
the difficulties encountered in T3 receptor isolation. The scene was dramatically 
altered when molecular biologists-entered the field. Cloning the cDNAs for estrogen 
and glucocorticoid receptors, which were easier to purify, allowed their sequencing 
which indicated their relationship to the viral oncogene erbA [102,103].(v-erbA is an 
avian[bird] retrovirus responsible for the development of erythroblastosis in chicken. 
Two domains of the retroviral genome play a cooperative role in the full expression of 
viral function. The cellular homologue of the v-erbB gene had been shown to code for 
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epidermal growth factor receptors [104]. The other gene, v-erbA, was also known to 
have a cellular homologue both in chickens and in humans, in whom it is located on 
chromosome 17 [105]). 
Reasoning that other hormones acting on the nucleus might be structurally related, 
Weinberger [106] and Sap [107] probed cDNA libraries for v-erbA related cDNAs, 
Weinberger recovered a "P" type from a chicken cDNA library. When the cDNAs 
were transcribed and translated in vitro, they coded for proteins which (in a sense 
f 
miraculously) bound thyroid hormone with an affinity similar to that recognized for 
receptors extracted from liver nuclei, and had affinities for thyroid hormone analogs 
characteristic of the naturally occuring receptors. Thus the cellular thyroid hormone 
receptors appear to be the proto-oncogenes from which viral oncogenes have 
developed [107:. 
Subsequent studies in rat and man have shown that at least four types of receptor or 
receptor-like moleocules are present. hTRp is encoded by a gene present on 
chromosome 3，and is a physiologically functional receptor [108]. hTRal is a closely 
related form coded by a gene on chromosome 17，and has a binding affinity for T3 
and related analogs characteristic of receptors present in rat and human tissues, and is 
also a functional receptor. hTRa2 is encoded by the same gene as is a l on 
chromosome 17，but is generated by alternative splicing of the mRNA precursor. In 
vitro studies suggest that hTRa2 may bind small amounts of T3, but in vivo analysis 
: in transfection studies indicate that it is inactive [109]. 
Most evidence overwhelmingly supports the view that these erbA related TRs 
represent "the" thyroid hormone receptors which are present in human and animal 
tissues. These receptors share their structure (fig 1) with a group of c-erbA related 




testosterone, vitamin D, retinoic acid, and probably other ligands [110]. All TRs have 
an NH2-terminal domain that is thought to partially control efficiency and specificity 
of gene activation [111], and which may contain sequences targeting them to the 
nucleus [112], a central DNA binding domain, a hinge region, and a COOH-terminai 
ligand binding domain. The DNA binding sequence' of the TRs contains two copies of 
a motif including four cysteine residues coordinated to a zinc atom which is believed 
to form a finger-like structure [16,113]. These proteins are of the "two zinc finger" 
family of DNA binding proteins. One finger is believed to fit into the major groove of 
the DNA alpha-helix [114,115] and bind specifically to a sequence of nucleotides 
comprising the thyroid hormone receptor response elements(TRE), while the second 
finger contacts the DNA in another manner, or may interact with other components of 




Fig 1: Structure of thyroid hormone receptors (TRs) 
Reproduced from Degroot [131] 
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SOME STUDIED GENETIC MODELS OF THYROID HOKMONE ACTIONS 
z 
The most extensively studied model of thyroid hormone action is the gene coding for 
rat pituitary GH. In thyroidectomized rats, the pituitary gland is virtually devoid of 
GH [116]. Rat pituitary tumor cell lines (GH and GC cells) that synthesize and export 
this protein have been a particularly convenient model for studying thyroid hormone 
action [117]. Addition of T3 to a medium containing no endogenous hormone causes 
a prompt increase in the rate at which the GH is transcribed, and is promptly followed 
by an increase in the appearance of GH mRNA. Identification of a thyroid hormone 
receptor response elements (TRE) in the 5' flanking region of this gene has provided 
conclusive evidence that the pituitary GH gene is a direct target of T3. 
Thyroid hormone stimulates hepatic lipogenesis by increasing the levels of several 
lipogenic enzymes [118,119]. The molecular details of this process have been 
extensively examined in the case of malic enzyme [120,121]. Two mRNAs code for 
malic enzyme: one 27 S and the other 21 S in size. The lag time in their response to 
T3 differs. In hypothyroid rats, the 27 S mRNA rises within 90 minutes after T3 
administration, while no increase is apparent in the 21 S mRNA until 10 hours after 
T3 injection. Curiously, in euthyroid rats, both mRNAs are coordinately regulated, 
and increase about 2 hours after T3 is injected. These findings suggest that malic 
enzyme mRNA is at least in part directly stimulated by T3, an inference that has 
recently been verified by the identification of a TRE in the upstream region of malic 
enzyme. 
、 
Abundant evidence suggests that thyroid hormones exert a direct inhibitory effect on 
the expression of the genes for the a - and p-subunits of pituitary thyrotropin (TSH) 
[122,123], thus negating previous suggestions that these effects are mediated by a 
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specific pituitaiy protein induced by T3. T3 administration reduces the level of TSH-
subunit mRNAs in animals bearing implanted TSH- producing tumor cells. These , 
effects are apparent within 2 hours after the administration of T3. TREs have been 
defined and sequenced in the 5' flanking DNA of these genes [124: • 
1 
Stimulation of the Na+，K+ gradients from extracellular to intracellular compartments 
may account for a substantial proportion of thyroid hormone-induced thermogenesis 
[125]. Although there is only a modest 1.5 to 3-fold increase in the levels of the 
various subunit mRNAs, studies of clone 9 cells reveal an increase within 2 hours 
after the addition of T3 to the medium. Thus, despite the relatively small response, 
these results are compatible with a direct effect of T3 on the expression of the genes 
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AIMS OF THE PROJECT , 
1 
INTRODUCTION 
In the evaluation pf thyroid diseases, two fundamental questions should be 
‘ cons ide red . First is the metabolic status of the patient. That is, is the patient 
hormonally deficient, normal or in excess? Secondly, what is the etiology of the 
disease process responsible for the horaional inbalance or thyroid gland abnormality? . 
Tests that measure hormone concentration in blood are carried out in vitro and are 
basic to indirect assessment of thyroid function. Another catagory of tests attempts to 
measure more directly the impact of thyroid hormone on peripheral tissues. There are 
numerous biochemical and physiological changes related to thyroid hormone 
deficiency and excess [148](table 1). Unfortunately, these tests are non-specific, since 
they are often altered by a variety of non-thyroidal processes. So far, not many tests 
have been shown to be satisfactory for assessment of response of effector cells to 
thyroid hormones. 
The occasional uncertainty concerning the fidelity with which serum thyroid hormone 
and thyroid stimulating hormone(TSH) concentrations reflect the thyroid hormone-
dependent metabolic status in peripheral tissues has long motivated the search for 
tissue markers of thyroid status. In 1974, Gwinup and Ogundikpe [194] reported that 
LAP (Leukocyte Alkaline Phosphatase) activity was suppressed in thyrotoxicosis and 
elevated in hypothyroidism. Since this assay is available in most hospital clinical 
laboratories, and is relatively inexpensive, and simply requires a peripheral blood 
smear Refetoff [195] and co-workers explored its potential application in the 
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fable 1: Reproduced from Refetoff [143] ‘ j ： 
.•一 _ 
BIOCHEMICAL ANO PHYSIOLOGICAL CHANGES RELATED TO THYRO们 HORMONE DEFICIENCY AND £XC£S 
� ” ” DuxCfC* •‘ DtTXTNC, 
^ ^、 &咖 HT^OT^O咖 T^OTOXICOSXS 
I .Sleuboliim of Various Substflncca and Drugs ” - - ‘ • — - : - . - , - . - ， - , , . : , _ - - " . - . . " . . — 、 ： ， . 
• fractional turnover rate (ancipyrine."� I * 
cipyTonc,"^  propylthiouracil (PTU) and ‘ ， . ， 
methimazole,二。albumin，"： low^ensitv 
lipoproceins/" cortisoi,"^" zsid _ 
I Serum , 
Amino acios 
Tyrosine (Bisdng level and after 二。） I . ‘ 
Glutixrac acia一。 m ， „ I Proteins 
U^bumin—^  ‘ I j 
Sex steroia—omGing gloounn I r 丁 
Fcrridn-^^ ” [ 丨 / 
Lov/-<ieasity ipoproceins二'•二 [ | 
f tbroaecrin—® | 
Factor Vm—related andgen—^ . ^ 
Tissue plasTuinogen activsxor^* | 
TBC" i • ； 
‘ N I 
Hormones ‘ 
Insulin 
Response to giucose—^ i i, 
Reiponse to glucagon--^  * ！. 
Escradioi-IT/?, tsscosterone.—and i or N f 
. 二 t • ‘ 
Parathyroid, hormone (PTH) , | [ 
c o n c e n OTL ci o n 二 
Response to PTH administration^ i f 
Renin activity and a l d o s t e r o n e 二 I * 
Ciitecholamines"^ ® xnd norepinephrine二了 f f, 
Atnal natriuretic oeocide二* i 
E r v t h r o o o i e c i n - N or i ' 
LK-° • , Nor r 
Response to gonadotropin-reieasing i N 
, hormone (CaRH) '^ 
Probccin and response to sdmuiacion with f or N [ 
TRH, areinine, axid chlorproma:z::ne-'°"^ " 
Crowch hormone 
Kesponse co insuiin-^ *-^ ^ I N or i 
Response to TRH*^ ^ \ No change 
Calcitonin response to Ci丄—innision-**" I 
Enzymes 
Creatine phosphokinase,^ -^ * lactic f I ！,‘ 
dehydrogenase.^^ and glutamic oxaioacetic I 
transajninase-^ ^ i 
Adenylate kinase-^ * N i 丨 
Dopamine /7-hydroxylase-^  f I 
Alkaline phospbaca^ se二-⑶ if f 
Malic d e h y d r o g e n a s e ' ^ I T t 
An^ iocensin-converrine enzyme,"®-"^  alanine N t 
iminocransferasc,-^ ** and glucathione 
S-transfera^ c 二 ** 
Co-enzyme I 
Others ‘ 
L2o-D(hvdroxv vitamin Df" t N or i 
cAMP.*^ ' cvciic griaiiosine cnonoohosohate or i N or t 
(cCMP),=" and Fe二•^口 . • 
- r • __ I 
7； * 、 - • . - - 一 - - - - - - V 
I ‘M?:" I I 
C 丄二-284 I f 
Ciucase 
Concentration 二，"^‘s I i 
Fractional turnover during IV tolcrance t . 
Insulin hvcogiycemia•丄- Prolonged -
Bilirubin-"-^ " I： t 
Creatinine-'^  N or | [ 
Creatine-^ ' iX or f f 
Cholesterol/"-"" caroCene,^ "-^ "^ ® I 1 
onosohoiioids and lecithin产了。and 
triglycerides"^  站"^了。 | 
i i 
* ... ••• - . 厂 • • - - - • .... i « � -•： i 
： 一 • , 43-a 
- . . . - ！ 
» . . • . : • : • . • : 
篇、 I m • • . fi , • “ 
2 • . . . - ? 、. ！ 




‘ TABLE I V : 
； I 一 - — 
‘ - J I 
- , T A B L E 1 
DTJMNC EhjXDiC " 
Ejottt MrxsvsjCD HrroTBrrRomtsw TKTxorajacosrs 
n Fr== fatty acic^ m • . “ r ‘ 
3 Cardnoemoryomc antigen- ‘ 
ihJrine I t 
.cAMPC: - I 1 
；fter eoincohrine infusion''* No chaijge ‘ ，cCMP"^. - Norl i 
J Me KvciroxvDrolme."^  and bydroxyiysyl gly- ‘ 丨 
1 cosi<ie^ '« I 
)Cr«timne二 • ？ 
> Crcarinine-^ ^ •�， ; 
r 丁rrosine二。 _ ‘ 、 〔 ； . 
/ Nirr (af ter administrat ion of ” _ . • M I I 
Clutzmic acta-。 丨 ’,. 
T a u n a — [ • • t 
31 Carnitine-"' ， . ， | 
-Tvramine, trypcamine, and histamine二。 ’ ” I | 
IT-Hydroxycorricoids and ketogenic sceroids^^ - |丨 
J Red Blood Ceils , t j' 
s N 产 ^ ； p 
J I ‘ 1' 
1 - Hemogiobin^ ®^-"^  , f | 
Giucose-6-phosphate dehydrogenase a c t i v i t y ‘ | f 
I Reduced elutaiiione-" and carbonic army- ' , | 
] . - — I V 1 1 
Ca-AT73^ e activUv-^ ^ — — — ' 
} White Bloo<i Cells ' ” 1 卜 
I 入IkoHne phosphatase-" ' 1 I i： 
* a T ? o roducuon in mitochoncir ia-" — li 
H Adioose Tissue | 
,CAMP�9 ’ I I 
1 Lipoorotein lipase-" ‘ 
i Skeletal Muscle" ]• 丨 
J CAMP"' 
1 Sweut Glands -
1 Sweat electrolytes-®*' \ ^ 
I Sebum excretion rate-^^ ‘ 
[I Intestinal System and Absorpt ion , I f 
Basic electnc^ rhythm of the duodenum-" ：. | ^ 
Riboflavin absorption二" ‘ ^  [ L 
Ca absorotion-'"' | 
Intestinai transit and fecai fat-'' 
Pulmonarv Func t ion and Gas Exchange I 
Dezd so ace.-" hvpoxic ventilatory drive 严 and ‘ 
arterial pOf« ‘ 
iNeurological System and CSF . | 
Relaxation time of deep tendon reflexes (photo- ‘ , 
mocogram 二如） » 
CSF proceins-^ ® ’ 
Cardiovascular and, Circula tory System ‘ 丄 
Timing of the arteriai scmncis (QKd产 } * 
Left ventricular ejection time (LYET)"'^  二 .. 二-二 _..,_--—,—�..： I 
?re.«iection period (PEP)"， ‘ ‘ 
£CC 浏 丨 t 
Heart rate and QRS voltage ’ [ 
Q-Tc interval [ 
PR interval Flat or inverted Trai^ sient abnonnalib 
L^^on ar^ h^ thmia. A^oven^cular block . A.nai abnlUdoa 
！ - ^oTseo^ maturation (bone age by x-ray Dejayed (epiphyseal Advanced 
Sim 尸 。 d y s g e n e s i s ) 
• N — normal; f — increcaed; I 一 decreased-
f In cKitdrea. 
I In neonates. 
. • - • • . ； 
• ., .. • • , , . - - -•. - , • - ：,-^'-^. ； 
• 43-b . ‘ 
- - . , • . } 
Chap 2 
diagnosis and follow-up of thyroid dysfunction. 
The data demonstrated that LAP activity is usually elevated in hypothyroidism. In 
thyrotoxicosis, eight of nine values were within the normal range. All of the 
thyrotoxic patients, however, exhibited LAP scores greater than the mean of the-
normal group. For reasons that are not apparent, the data on the thyrotoxic patients 
are not in accord with the previous report of Gqwinup and Ogundipe, who reported 
low LAP scores in each of 14 thyrotoxic patients. 
4 
LAP activity appeared to be a very early indicator of a tissue response to thyroid 
hormone replacement. Although a transient, elevation was observed in two p a t i e n t s , . 
L A P activity remained at normal levels within the first 1 to 2. months of therapy in all 
patients. While study of a larger number of patients is required to characterize the 
acute response to T4 therapy, it is evident from the cases presented that the target 
tissue, granulocytes and/or bone marrow regulating granulocyte release [196-
199,132], is highly sensitive to thyroid hormone. 
The data presented in that paper need to be considered in the context of LAP's 
recognized characteristic as an acute phase reactant [133]. Elevations of LAP are not 
sufficiently specific for use in the diagnosis of hypothyroidism, since LAP values are 
also known to be elevated in many other situations (see below). The non-thyroidal 
causes of LAP elevation should likewise be considered in patients with recognized 
-hypothyroidism. 
The normal range of LAP score is wide [134], roughly around 35-100 in most 
laboratories. In a few normal individuals, occasionally some neutrophils score 3，but none 
score 4. The score is higher in women and children than in men, and in newborn infants 
the range is 150-300. 
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High scores are found in the neutrophilia of infections, in leukaemoid reactions, liver 
cirrhosis, Down's syndrome and polycythaemia vera [149]. The enzyme seems to be 
influenced by hormones such as estrogens and corticosteroids, which may explain the 
gradual rise in score in pregnancy. High scores are found in active Hodgkin's disease 
but they are uncommon in other malignant lymphomas [149]. 
I 
When elevated LAP activity is due,to hypothyroidism, a reduction of LAP activity is 
expected with the institution of hormone replacement and constitutes evidence.of a 
somatic response to therapy [150]. With further study, this capability may prove to be 
particularly helpful in patients in whom the serum TSH is not a reliable reflection of 





SUBCELLULAR LOCALIZATION OF FTTMAN NEUTl^OPHTT' ALKALINE 
PHOSPHATASE 
Some understanding of the localization of alkaline phosphatase within neutrophils is 
» 
necessary for gaining insight about the influence of thyroid hormones on levels of 
alkaline phosphatase within WBC.-.Such information is also critical for the validation 
of the technique for quantitative assay of leucocyte alkaline phosphatase. 
Controversy has arisen concerning the localization of human neutrophil alkaline 
phosphatase due- to the use of different techniques. Using biochemical and light 
microscope histochemical methods, the enzyme has been shown to be cytoplasmic 
[135], but with electron microscope cytochemistry, a variety of organelles have been 
implicated including the plasma membrane Golgi appartus and various vesicles 
[137,139]. Bainton et al. [140] localized alkaline phosphatase to the specific granules 
of myelocytes but were unable to detect any activity in mature circulating granulo-
cytes. Other workers, using subcellular fractionation techniques, have found the 
enzyme in the "microsomal fraction" but not in the specific granules of mature cells 
[141,142]. A new approach combining analytical subcellular fractionation and 
electron microcope cytochemistry [143] has been applied to the study of alkaline 
phosphatase's location in human polymorphonuclear leucocytes and has shown the 
enzyme to have a unique localization, as will be discussed. 
By using classical biochemical and light micrsocope histochemical methods [136]， 
alkaline-phosphatase activity can be demonstrated in the cytoplasm of mature 
neutrophils, typically in the segmented forms and only very occasionally in band 
forms. In 1958, Hayhoe and Quaglino [135] used a modification of an azo-dye 
coupling technique and showed LAP activity in neutrophilic leucocytes to be limited 
exclusively to the cytoplasm of the cell. In 1969, Spicer and Hardin [136] further 
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localised LAP activity to the specific granules of mature neutrophils. 
Neutrophils exhibit highly specialized morphology and biochemical features which 
seem to be adapted to a role whereby these cells provide "shock troops" for initial 
combat with invaders. Because of its content of hydrolases and other antibacterial 
agents, the cytoplasmic granule is the organelle of the neutrophil equipped for 
destruction of bacteria. Electron • micrographs of rabbit heterophils in an early 
(premyelocyte) stage of development reveal a homogeneous population of relatively 
‘ l a rge (ca. 800 mu) granules which stain intensely with uranyl acetate [151]. These 
granules, which correspond with the azurophil granule seen by light.microscopy, have 
been designated primary, granuks [152]. These are the first granules synthesized in 
developing heterophils. Ultrastructural and light microscopic cytochemical methods 
demonstrate nonspecific acid phosphatase in heterophil primary granules and in the 
structural Golgi elements participating in their synthesis, indicating that granules of 
this type may be considered lysosomes. 
Electron micrographs of rabbit heterophils at an intermediate (myelocyte, 
metamyelocyte, and band) stage of development in the marrow reveal an additional, 
smaller (ca. SOOmu) and less dense type of granule [153], which corresponds with the 
specific granule at the light microscopic level; it has been termed the secondary 
granule in reference to its synthesis relatively late in cell development. Biogenesis of 
secondary granules is said to proceed through budding of precursor vacuoles from the 
convex face of the stacked Golgi lamellae [154]. 
Secondary granules, as well as the Golgi elements involved in their genesis, show 
activity for nonspecific alkaline phosphatase, rather than acid phosphatase. The 
only other cytochemical knowledge of these granules concerns their high 
concentration of cation, presumably Na+, as evidenced by the difiuse precipitates seen 
in the secondary granules after fixation with Komnick's pyroantimonate-osmium 
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tetroxide elution [155]. 
The concept has long been held that azurophil (primary) granules of human and other 
species are somehow transformed into specific (secondary granules).On the other 
hand later evidence strongly supports the concept that secondary granules arise by de ‘ 1 
novo synthesis from the Golgi complex [152]. The Golgi complex involved in 
formation of secondaiy graniiles is strikingly different morphologically and 
cytochemically from the Golgi complex involved in formation of primary granules. 
Electron micrographs of late, segmented heterophils in circulation reveal a smaller 
third type of granule, which measures up to 300 mu m .grea tes t dimension. These has 
been termed, the tertiary granule [152]. The significance of the heterogeneity of the 
granules in neutrophil leukocytes remains s p e c u l a t i v e ; however, the variety cpf stored 
granules conceivably results in availability of a broader spectrum of hydrolases and 
other antimicrobial substances than a single granule type could provide. 
In experiments of phagocytosis of bacteria by heterophil leucocytes [137]，acid 
phosphatase-reactive granules were frequently observed immediately adjacent to 
phagocytic vacuoles and, in some instances, fusion of these structures was apparent. 
Similarly, granules showing alkaline phosphatase reaction product deposition occured 
in dose association with phagocytic vacuoles. Alkaline phosphatase reaction products 
were visualized with these vaccuoles, providing evidence consistent with the 
suggested fusion of such granules with phagosomes. : ——…— 一 
Subcellular fractionation studies of rabbit neutrophils clearly demonstrated alkaline 
phosphatase activity in- the specific granule [145]. Similar studies on human 
neutrophils have, however, shown the enzyme to be localized to microsomes and not 
in the specific granules [146]. Microsomes is an operational term for the heterogenous 
collection of membranes, derived from plasma membranes, mitochondrial outer 
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membranes, Golgi apparatus and the endoplasmic reticulum, obtained by high-speed 
centrifugation of tissue homogenates. These components can be resolved by analytical 
sucrose density gradient centrifligation, particularly if combined with selective 
membrane perturbants such as digitonin. These techniques have been used to 
investigate the intracellular localization of alkaline phosphatase in human neutrophils. 
I 
The fractionation procedures have been complemented by EM cytochemical studies 
on intact cells, homogenates and density gradient fractions. Special attention has been 
paid to the use of procedures which minimize enzyme inactivation and non-specific 
lead precipitation. The results of this combined approach have been to demonstrate ‘ 
the localization of alkaline phosphatase to a previously unrecognized organelle [147]. 
The majority of neutrophil alkaline phosphatase activity was localized in a population 
of cytoplasmic granules which characteristically contained heavy deposits of reaction 
product associated with the membrane. These organelles showed a variety of shapes 
in sectioned material including regular spheres, elongated rods, irregular spheres, 
ellipses or irregular, elongated tubular structures sometimes with a branched or 
twisted profile. 
In those studies, alkaline phosphatase is clearly localized to a discrete organelle which 
has been designated the 'phosphasome' [147]. In normal cells only trace amounts of 
activity are present in other staitures including plasma and nuclear membranes，endo-
plasmic reticulum and azurophil granules. The phosphasomes sometimes have a 
superficial resemblance to mitochondria and 丨n tissuesjlch in these organelles, alkaline 
phosphatase reaction products may be seen in mitochondria. However, mitochondria 
are only very rarely seen in mature neutrophils and no reaction product was seen in 
them. In immature cells where mitochondria are more frequently seen, no reaction 
product is present in these organelles. Subcellular fractionation experiments [143] 
have clearly shown that alkaline phosphatase is not located to the mitochondria and 
studies on leukocyte mitochondrial ATPase have distinguished this activity from 
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alkaline phosphatase. Phosphasomes may be identified in unstained sections and 
perhaps correspond to the so-called tertiary granules described previously. ^ 
In summary, localization of alkaline phosphatase within human neutrophils is still an 
open question. Nevertheless, all investigations mentioned above indicated that the 
alkaline phosphatase activity resides predominantly within cytoplasm. Lysing leuco-
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PROSPECTS FOR A QUANTITATIVE Ai�S AY OF LEUrorYTK ALKALINE 
PHOSPHATASE WITHTN L E U C O C Y T E S � 
z 
The results of LAP scores varies enormously between different laboratories and even 
different technicians within the same laboratory. This is largely due to the nonuniform 
t 
scoring systems involved. 
The score in an individual film consists of the sum of the scores of 100 consecutive 
neutrophils. As this mode of assessment is subjective, each laboratory establishes its 
own normal range. 
The limitation of the LAP score for correlating with any pathological process is 
obvious. Since alkaline phosphatase is an enzyme readily measurable in most 
laboratories, quantitative measurement should probably be prefered over cytochemical 
staining methods. It was our intention to develop a workable, accurate procedure for 
quantitative assay ofleucocytic alkaline phosphatase, and then to assess its usefulness 
in thyroid patients as a cellular marker for thyroid status. 
In patients with severe or longstanding hypothroidism, it 呵 require three to six months 
of hormone replacement before TSH levels are fully suppressed. In Refetoff s paper， 
LAP activity appeared to be very early indicator of a tissue response to thyroid hormone 
replacement. Although a transient elevation was observed in two patients，LAP activity 
remained at normal levels within the first 1 to 2 months of therapy in all patients. 
‘ 51 
Sometimes, increase in the sensitivity of certain tests may enhance their usefulness for 
investigation of pathological conditions. One example is sensitive TSH. The 
traditional assay cannot distinguish normal from decreased levels of plasma TSH, and 
therefore is not useful in the diagnosis of thyrotoxicosis. New immu no metric assays 
offer a many fold increase in sensitivity，thus rendering them. as a first line test for 
diagnosis of thyrotoxicosis. Whether the same would occur for a quantitative 
leucocyte alkaline phosphatase assay serving as a cellular marker reflecting thyroid 
status of patients seemed worthwhile investigating. 
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Volunteer control subjects were available from fellow staff and friends of The 
Chemical Pathology Department, PWH. They were known to be free of thyroid 
disorders based on .clinical assessment and thyroid function tests results. Patient 
subjects were available from the Thyroid Clinics at the Prince of Wales Hospital, 
Hong Kong. They were labeled normal, thyrotoxic, and hypothyroid according to 
clinical assessment and thyroid function tests. Consent forms (Appendix IH)； 
approved by the Ethics Committee of the Chinese University of Hong Kong, were 
signed by patients prior to venepuncture. 
SPECIMEN rOTXECTIQN 
About 7 ml ofheparinised blood and 5 ml. of clotted blood samples were taken from 
each subject. Severa l peripheral smears were made for LAP score, and processed 
within 2 hours. WBC were isolated from 5 ml of whole blood. The cell pellets were 
frozen at -70 C, and assayed for alkaline phosphatase and protein on the next day. 




ISOLATION OF WHITE BLOOD CELL , 
Leucocytes were separated from the rest of the cell population as follows. 
A classical Percy and Brady [156] method was used. 20% V/V of dextran solution 
(50/0) was mixed with whole blood knd allowed to stand for 45 min. The supernatant 
containing WBC was extracted. RBC that remained in the extract were removed by 
isotonic shock and washing steps. 
To get samples with similar quantities of leucocytes for the o p t i m i z a t i o n studies-of the 
alkaline phosphatase and total protein assays, a whole pack of blood was obtained 
from polycythemia patients receiving therapeutic vensection. The whole pack of blood 
(about 300 ml) was treated as above. The supernatant was divided into equal 
aliquots, so that the quantity of WBC in each subsequent aliquot was identical. 
Although LAP score tends to be higher for polycythema patients, the blood received 
provided convenient and suitable samples for our purpose. 
The principle of the isolation process is that when whole blood is allowed to stand at 
room temperature for about 45 minutes, leucocytes, whose buoyant density is less 
than that of red cells, sediment more slowly and form a "buffy coat" between the 
erythrocytes and the supernatant plasma. I f the density of the medium through which 
sedimentation occurs is increased, —e.g.，by addition of dextran, leucocytes remain 
suspended. Recovery of the supernatant and centrifligation at low centrifugal force 
results in a pellet made up largely of leukocytes. Contaminating erthrocytes can be 
eliminated by isotonic shock treatment, since they are less resistant than white cells to 
lysis in hypotonic solutions. 
In the optimization process, 5 ml of blood collected in acid- citrate-dextrose was the 
1 . . . . . - • • • • • 
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source of white blood cells. Leucocytes were separated within 2 hours of sampling. A 
considerably smaller yield of leukocytes is obtained from heparinized biood from ^ 
. • 
clinical samples unless the isolation is carried out within a few hours after the sample 
is drawn [156]. Furthermore, the inclusion of glucose (dextrose) in ACD solution B 
helps maintain leukocyte viability during prolonged storage. 
The protocol for isolation of leucocytes was as follows: 
Reagent: ‘ 
5% Dextran is prepared by dissolving 5g dextran T150 (average M.W: 254000)，0.7 g 
NaCl and 50mg heparin iirlOO ml distilled water. 0.9% NaCl and 1.8% NaCl is made 
up by dissolving 9 g and 18 g of NaCl respectively in 1000 ml DW. 
V 
Procedure: 
1 part dextran solution is mixed with 4 parts blood (eg. 2 ml + 8 ml).The solution is 
gently mixed and is then stood at an angle of 45 degrees for 30±5 min at room 
temperature. The supernatant is then removed and centrifuged for 10 min at 600G. 
The supernatant after centrifugation is drawn of f and discarded. The pellet o fWBC is 
then resuspended in 1 ml cold 0.9% NaCl 3 ml of cold distilled water is added to the 
. p e l l e t and mixed gently. After 45 s 3 ml of cold 1.8% NaCl is added. The pellet. 
suspension is then centrifuged at 500 G for 10 min. The supernatant is then drawn of f 
and the shock treatment repeated. Traces of liquid are then drawn off. The WBC 
———pellet inlhe vials is then stored at -70 C. 
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Chap 4 
LYSIS OF LEUCOCYTES 
There are several common ways to lyse cells, namely, homogenisation, freeze and 
thaw, detergents and ultrasonication (usually c o u p l e d to one of the other methods). 
» 
The choice of method depends on the intended purpose. 
% 
A homogenisation step is inappropriate since this usually applies to quite large 
quantities of sample. Even i f a facility for micro-homogenisation were available, what 
we are confronted with is a very small amount of leukocytes isolated from about 5 ml 
of blood. As a.result, even.small losses of cells wil l cause quite a large etror in our 
• • . 
precision studies. 
V 
The freeze and thaw method has been used for enzymes of some other cells, such as 
red blood cells. However, it was found that the effect on lysis was not very good for 
leucocytes as verified by viewing the lysate under the microscope. 
The last choice is by using detergent. There are several classes: anionic detergents, 
cationic detergents, non-ionic detergents and a class of detergents which cany both 
positive and negative charges (amphipathic). For enzyme systems，non-ionic 
detergents are the ones of choice, since it is difficult to estimate to what extent the 
charge carried by the detergent will influence enzyme activity under the varying 
conditions of the assay. : . — — 
I t has been found that detergents may have positive or negative effects on the activity 
of enzymes. They may also interfere with protein determinations. In the assay of 
proteins in some trial runs, the effect of detergents was dramatic, as shown at fig 1. 
For example, Triton-X has very dramatic negative effects on the protein assay. The 






Fig i ； Effects of Triton X and saponin on protein assay. -
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The bias of Triton-X on Bradford's method for protein assay is dramatic in comparison with 
that of saponin, rendering the latter more suitable as a detergent incorporated in solutions for 
protein assay. 
t 
• _ . . . . . . . 一 .• ‘ 
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Subsequently, saponin was chosen as it gave a reasonably small change of absorbance 
over the range 10 to 50 mg/L of protein. It was found that the effect of lysis of 
leucocytes by saponin was good. Concentrations of saponin greater than 0.5% 
resulted in WBC lysates free from cell debris under light microscope. It does have 
i 
some effects on protein measurement, however, but these could be corrected for by 
incorporating similar concentrations of saponin into appropriate standards. 




ASSAY FOR T O T A L PROTEIN 
Since the WBC count varies appreciably between patients, it was necessary to take 
this into account in expressing alkaline phosphatase activity. Therefore, the specific 
activity (amount of enzyme activity per unit amount of protein) was derived. It was 
I 
• therefore necessary to measure total protein in the sample. 
METHODS FOR PROTEIN DETERMINATION 
Methods available included the copper-phenol method of Lowry [160], direct UV 
spectrophotometry, turbidity measurement following protein precipitation for rapid 
approximate determination, and the dye binding methods very commonly used for 
determination of albumin. 
Many methods have been based on Lowry's original method (1951). Bradford's 
method [161] was used in this study. 
-— -_ “ 
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PROTEIN MEASUREMENT USING BRADFORD'S METHOD 
z 
Bradford's method is a dye-binding assay based on the differential colour change of a 
dye in response to various concentrations of protein. In research applications, this 
assay is recommended as a replacement for other protein assays, especially the widely 
used Lowry's method, for several reasons. 
Firstly, Bradford's method is much easier to use. It requires one reagent and five < 
minutes to perform as compared to three reagents and 30-40 minutes typically for 
Lowry's method. 
Secondly, Bradford's method is free from most of interferences which limit application 
of the Lowry assay. The absorbance of the dye-protein complex is relatively stable. 
The principle of the assay is the "Protein error of Coomassie Brilliant Blue G250", 
based on the shift of the absorbance maximum for acidic solution of CBB-G250 from 
465 nm to 595 nm when binding to protein. 
- 、 - -
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Reagents were obtained from Bio-Rad, USA (Protein assay reagent concentrate 
containing Coomassie Blue G250; available as : 500-00006 Bio Rad Protein Assay Dye 
Reagent concentrate, 450 ml). 1 ml of concentrate was diluted with 4 ml distilled water 
for a working reagent. This concentration was modified from the original Bradford's 
method, for the Cobas Bio analyser (see Fig.2). The assay range was 12 - 250 mg/L. 
Samples were diluted with saline i f results were over 250 mg/L. 
Fig 2: Parameter listing on Cobas Bio for Bradford's method. 
J 
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ESTABLISHMENT OF CONDITIONS RELATED TO PROTEIN ASSAY 
I t was necessary not simply to establish the method, but to see i f it was valid for 
samples containing detergent (saponin). A step by step approach had to be adopted 
to establish the exact conditions for the protein assay. 
n、Tnterference on protein measurement bv saponin 
To investigate such effects, equal amounts of bovine serum albumin (BSA) were 
mixed with equal volumes but variable concentrations of saponin. The final 
concentration of total protein in each reaction cup was the same. 
V 
[Table 1]: Interference on protein measurement by saponin 
measured value expected value 
of protein(mg/L) of protein(mg/L) 
BSA in 0.1% saponin 494 400 
0.2 577 400 
0.5 756 400 
1 1053 400 
2 1622 : 400 — 
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From the graph shown in fig 3, it seems that 1% saponin would give too great a bias 
(approximately 2.5 times) to be practical. Standard curves with a final concentration ‘ 
of detergent less than 0.1% saponin were used for assaying protein content in the 
reported studies. 
» 
Fig 3; Interference on protein measurement by saponin,, 
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In another experiment, the effect of lower concentrations of saponin was observed on 
the protein assay by Bradford's method. Samples of known protein content were 
made up by dissolving known amounts of BSA (bovine serum albumin) in dinerent , 




Interference by different concentrations of saponin on protein assajr, 
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concentrations of <0.1% saponon provides reasonably small interference for protein assays. 
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The effect of saponin on Bradford's method of protein determination is to produce a 
positive bias (i.e. measured values higher than actual protein amount). Since a 
constant concentration of detergent was always present, standard curves were 
established with standards containing similar concentrations of saponin to those in 
specimens. 0.01% saponin was chosen as the final detergent concentration for 
samples being assayed for protein content. In the study, the WBC pellets prepared 
from patient samples were each lysed by 2 ml of 1% saponin. 200 ul of each lysate 
were taken for assay for alkaline phosphatase (see below). The remaining portions of 
those lysates were diluted with D.W. to a final concentration of 0.01% saponin. 
V 
. . . . . - • - . - - • . . . - -1 - . 
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⑵ L inear i ty of standard curve for assay of leucocyte protein dissolved in 
0.01% saponin. 
In this experiment, a range of known protein concentrations (see Table 2)，all of 
which were in 0.01% saponin, were assayed using the standard protocol. The 
apparent protein concentration is plotted against the actual protein content in fig 5. 
* 
[Table 2]: Apparent protein concentration against actual protein level. 








A regression equation can be calculated from data of fig 5: 
[apparent protein](mg/L) = 1.03 x [actual protein] _ 5 
. Point I, II，: I I I , I V and V represent ..a serial dilution of a single sample of WBC to 
observe the linearity of the assay when WBC protein was diluted with 0.01% saponin. 
From the curve shown in fig 5, the specimen dilution in 0.01% saponin appears to 
show similar b e h a v i o u r to BSA dissolved in saponin. Again，in the assay used in the 
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study, the standards were diluted in saponin 0.01% which would help to correct for 
the bias introduced by the saponin. 
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Results of actual protein content in a solution with 0.01 % saponin can be interpolated from a 





I n protein assays for patient samples, three standards of 62.5，125 and 250 mg/L in 
0.01% saponin were used to establish a standard curve. The protein concentration 
was then read from the curve. Fig 2 shows the parameter listing of the Cobas Bio for , 
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ASSAY OF LEUCOCYTE A L K A L I N E PHOSPHATASE 
DETERMINATION OF ALKALINE PHOSPHATASE 
t 
Principle: 
This is a procedure adapted from Bowers and McComb [162,163,164]. 
Para-nitrophenyl丨"losphate(PNPP) is colorless. The enzyme splits off the phosphate 
group to form fn： e p-nitrophenol(PNP), which in the acid form in dilute solution is 
also colorless. Uii-ier alkaline conditions this is converted to the p-nitrophenoxide ion, 
which assumes a ([uinoid structure with a very intense yellow color. At the pH of the 
reaction, most of i;he free nitrophenol is in the yellow-colored quinoid form. Thus； the 
course of the reaction can be followed by observing the increase in yellow color. At 
the pH of the reaction, not all of the phenoxide is in the quinoid form, but the fraction 
is constant for any one assay, and the rate of color formation can be used as a 
measure of the reaction. 
The rate of formation of p-nitrophenol (PNP) by the action of the enzyme on p-
nitrophenylphosfbate at 30 C can be monitored colorimetrically with a recording 
spectrophotometo'. Substrate, buffer/P〇4-acceptor，and Mg2+ are at the optimal 
concentrations ol. 1.4X10-3，o.75, and 1.0X10-4 mol/1, respectively. 
— - . . . _ -• 
Reagent: 
Stock buffer is prepared by dissolving 500 g 2A2M1P (2 amino-2 methyl-1 propanol) 
in 1000ml DW and storing at 4 C. Working buffer (0.89 mol/L pH 10.33 at 30OC) is 
prepared by adding 160 ml of stock buffer to 500 ml DW and then 160 ml of 1 mol/L 
HCl. MgCl2 (1.5 mmol/L) is prepared by 300 mg MgCl2.6H20 in lOOOml DW. p- … 
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nitrophenylphosphate (210 mmol/L in 105 mmol/L MgCl)) is prepared by dissolving 
0 . 0 6 1 g of disodium p- nitrophenyIphosphate .6H20 in 1 ml MgCb solution. The 
subtrate was prepared fresh and stored no longer than 1 week at 4 C. 
Assay procedure: , 
The method was modified and automated on a centrifugal analyser (Cobas Bio, Ro.che 
Company, Basle, Switzerland) and the parameters are listed in fig 7. 
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Fig 7 iParameters for automated method determination of alkaline phosphatase 
Units U/L 
calculation Factor 267 
Standard 1 conc 0 ‘ 
2 0 
3 0 . 
Limit 27 
Temperature [ Deg. C] 37.0 
Type of Analysis 3 
Wavelength(nm) 404 
Sample Volume [UL] 50 
Diluent Volume [UL] 15 
Reagent Volume [UL] 13 5 
Incubation time [sec] 300 
Start Reagent Volume [UL] 10 
Time of First Reading [sec] 10.0 
Time Interval [sec] 100 
Number of Readings 21 
Blanking Mode 1 
Printing Mode 1 
50 ul of sample was incubated with 135 ui of working buffer at 37 C for 5 min. 10 ul 
of p-nitrophenylphosphate solution were then added into the reaction cuvettes and the 
absorbance measured after centrifugal mixing. The first reading was taken 10 s after 
mixing. Absorbance was then measured at 20 s intervals. 21 readings were taken. The 
result, expressed as lU/L, was calculated from change in absorbance/unit time. The 
change in absorbance/unit time is assessed by the instrument automatically from the 
70 
Chap 3 
linear part of the curve. 
The activity is calculated from the formulae: 
change in absorbance 




F is derived from molar absorptivity s for the product, p- nitrophenoxide (yellow, 
t 
quinoid form). In this case, s is an established constant (=18750 for PNP). 
The most widely accepted and sensitive method for alkaline phosphatase assay is to 
use NPP (p-nitrophenylphosphate) as substrate and AMP (2 methyl - 2 
aminopropanol - 1) as buffer. AMP has enhances phosphatase activity and has 
replaced the inhibiting glycine buffer of the older procedures. 
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THE EFFECT OF DURATION OF INCUBATION TIME WITH DETERGENT 
ON ENZYME ASSAY — 
The time for the lysis of white blood cells prior to process of enzyme assay was very 
critical. I t takes time for detergents to lyse cells, However, after a certain period, it 
I 
can be observed that the suspension becomes more and more cloudy. The reason is 
that micelles begin to develop, i.e., the membranous phospholipids reorganise 
themselves again into micelles [157,158]. This is likely to influence the ehzyme 





In one single experiment, several samples of a WBC preparation containing the same 
amount of WBC were used. The cells were lysed by addition of 1% sapomn(2 ml). 
The incubation time for each cup was varied. All the samples were assayed together 
and immediately after incubation. 
[Table 3]: Relationship between incubation time and measured activity, 
saponin incubation measured 
concentration time activity 
lU/L 
<Ciba Corning QCS normal control〉 54.7 
1% 60 min 7.3 
1% 45 20.1 
1% 30 23.4 
1% 15 20.6 
1% 0 31.7 
< QCS abnormal control 〉 179.4 
73 
Chap 3 
From the actual result data of table 3, a plot of incubation time against leucocytic 
alkaline phosphatase activity was made (fig 9). 
Fig 9 : Incubation time plotted against leucocytic alkaline phosphatase activity. 
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From fig 9, it seems that lysis of cells by 1% saponin is very rapid, and the onset of . 
micelle formation and enzyme/protein denaturation does not take effect until after 
about 45 min. The drop in activity was very slow, so that activity can safely be 
assayed within 30 min. of lysis. However, to insure reproducibility, samples were 
assayed after 15 minutes incubation. This short incubation period had the advantage 
t 
that it reduced the probability of micelle formation and reduced enzyme activity.. 
t 
=. . . • • - • — 
75 
Chap 3 
i m EFFECT OF DETERGENT CONCENTRATION ON ENZYME ASSAY 
Several WBC pellets containing the same quantity of WBC were used. These WBC 
pellets were lysed by different concentrations of saponin (from 0% to 2%). After 
incubation for a fixed time (15 min), the lysed suspensions were assayed for alkaline 
phosphatase activity by the standard method described previously. 
[Table-4]: Effect of different concentrations of saponin on alkaline phosphatase 
activity. 
saponin Incubation Activity ‘ 
concentration time 
<QCS normal control〉15min 56.2 
0.1% ’’ 19.4 
0 . 2 % ，， 25.4 
0 . 5 % ，， 26.4 
1。/o ，， 30.4 
2 % ，， 17.3 
<QCS abnormal control〉:,’ 184.7— 
76 
等 •庫 - - • 
Chap 3 
Result: 
A plot of measured activity ( change in absorbance/ min) as against saponin 
concentration is shown in fig 10. 
J 
I t can be seen that optimal concentration of saponin employed lies around 1%. This 
was the concentration of saponin selected for lysis of WBC. 
Fig 10: Effoct Of differsnt concentrations of saponin on alkaline-
phosphatase actmty. 
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THE EFFECT OF PROTEIN AMOUNT ON THE MEASUREMENT OT 
ACTIV ITY OF ALKALINE PHOSPHATASE 
Variable amounts of protein with no enzyme activity (bovine albumin) were added to 
several samples from a single lysate suspension, so that the protein amount of each 
sampling cup varied but the actual enzyme content remained the same for each cup. 
Procedure: 
A WBC pellet was lysed with 1% saponin and 1 /lO dilutions made using 1% 
saponin. The diluted WBC lysates were incorporated with different amounts o fBSA 
and assayed for alkaline phosphatase activity. 
The results are shown in table 5. 
[Table 5]: Measured alkaline phosphatase activity against different protein content of 
samples. 








Result of Table 5 showed that the enzyme activity measured was not influenced by 
different protein content in the samples (fig 11). 
I 
Fig 111 Effects of different protein content of samples on 
‘ alkaline phosphatase actmty- . 
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OPTIMUM pH OF WORKING BUFFER FOR ALKALINE PHOSPHATASE 
In this experiment, a single WBC preparation was assayed for alkaline phosphatase 
activity using working buffers adjusted by HCl to different pHs. The results are shown 
in table 6. 、 
[Table 6]: Effect of pH of working buffers on measured activity of alkaline 
phosphatase. 












EFFECT OF TIME LAG BETWEEN FREEZING AND WBC PELLET 
PREPARATION ON MEASURED ACTIVITY OF LEUCOCYTIE ALKAL INE 
PHOSPHATASE 
I t usually takes quite a while for WBC pellets to freeze within a standard refirigerater 
(-70 C). This time lag may result in leakage of cellular contents and deterioration of 
enzyme molecules within the cell. To validate our standard procedure for preparation 
and storage of WBC pellets, an experiment was conducted to show that the short time 
lao- involved did not affect alkaline phosphatase activity. 
This experiment was done on samples from patients. WBC from two cases were 
divided into 2 equal parts. One of the WBC pellets was immediately frozen in liquid 
nitrogen, while the other was frozen by simply placing it into a paper box, then storing 
within a -70 C. refrigerator. All those were assayed the next day. Ciba Corning 'QCS 
normal' was used as an assayed control. 
The specific activity of leucocytic alkaline phosphatase (SA- LALP) results were as 
follows: 
sample liquid nitrogen treated standard freezing 
procedure 
1 58.6 mU/mg 59.3 mU/mg 




I t is concluded that the time lag prior to freezing of WBC pellets did not affect the — 






E2EEQI OT E E Q L Q H Q E n S I Q M Q S OT M E M I QH A e i m i X OT 
T .F.TTCQCYTE ALKALINE PHOSPHATASE 
I 
Frequently prolonged storage of frozen cells causes deterioration of enzyme activity. 
The purpose of this experiment was to show that this did not occur for alkaline^ 
phosphatase in WBC when stored at -70 C. for one month. 
Samples were taken from patients. Again, samples from two cases were processed -
each s a m p l e was divided into two parts. One of the WBC pellets was assayed 
routinely，while the other was assayed one month later (stored at - 70 C.). 
Ciba Corning (Irvine,USA) "QCS normal" was used as an assayed control. 
The results of SA-LALP (mU/mg) are tabulated in Table 10. 
• - % 
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[Table 10]: Effect of prolonged storage on activity of leucocyte alkaline phosphatase. 
sample overnight storage 1 month storage 
1 48.3 mU/mg 45.6 mU/mg 
2 38.4 mU/mg 35.3 mU/mg 
I 
Prolonged storage of WBC pellet did not affect enzyme activity appreciably. Since the 
enzyme assays were done one day after preparation of WBC pellets, such effects 





O T H E R ASSAYS 
LEUCOCYTE ALKALINE PHOSPHATASE SCORE 
I 
Principle 
A number of techniques have been devised for'this study. The method o f Kaplow 
[165], modified by Hayhoe and Quaglino [166], was selected because it gives 
reproducible results which facilitate subsequent scoring and reporting. The reaction 
depends on the hydrolysis of alpha-naphthyl phosphate by alkaline phosphatase to 
produce a colored precipitate with a diazotized amine. 
Reagents 
Fixative is made up of 9 parts of absolute methanol with 1 part of 40% 
formaldehyde. Stock buffer solution is prepared by dissolving 10.5 g of 2-amino-2-
methyl propane-(l:3)-diol in 500 ml of distilled water. The working solution is made 
up by mixing 25 ml of stock solution, 5 ml o fO . lN HCl in 70 ml of distilled water, 
and is then stored at 4 deg.C. Substrate is made up by mixing 20 mg sodium alpha-
naphthyl phosphate, 20mg of Brentamine-fast garnet (GBC) salt together with 20 ml 
of working buffer. The substrate must be prepared fresh and filtered just before use. 




Freshly prepared blood smears are made from venous blood, and fixed for 30 seconds 
at 4 deg.C. The smears are washed with distilled water and allowed to air-dry. 
Substrate is poured on and allowed to remain for 10 to 15 min. The smears are 
counterstained for 10 to 15 min. Excess water is drained off and the smears are air 
dried. A red-brown precipitate in the cytoplasm indicates alkaline phosphatase 
activity. Control slides would preferably show high and low values, e.g. films from 
pregnant women and from patients with untreated myeloid leukemia. These may be 
stored in a fixed state for a consideratbie time. Small batches of slides should be 
stained at one time since timing is important i f scoring is to be used. 
The slides are scanned as soon as possible after preparation since the stain tends: to 
fade, particularly in weakly reacting cells. 




Kaplow's scoring values for neutrophils are as follows: 
0: Negative. 
1： Barely visible diffuse staining with an occasional positively stained granule. 
2: Diffuse staining with moderate granule formation. 
3: Strong positive with numerous granules. . 
4: Very strong positive with much of the cytoplasm filled with precipitate. 
One hundred neutrophils are examined and the individual scores added together. The 
normal range is from 30 to 100，although individual laboratories may seek a closer 




ASSAY FOR TSH 
The Ciba Coming (Medfield’USA) ACS TSH assay is a two-site chemiluminometric 
(sandwich) immunoassay, which uses constant amounts of two antibodies. The first 
antibody or Lite Reagent is a monoclonal mouse anti-TSH antibody labeled with 
acridinium ester. The second antibody or solid phase is a polyclonal sheep anti-TSH 
antibody covalently coupled to paramagnetic particles. . 
50 ul of Lite Reagent and 225 ul of solid phase is added to 200 ul of sample and 
incubated at 37 C for 7.5 minutes. Solid particles are separated from the mixture by 
magnetism and aspiration of the aqueous phase. Solid particles are then washed with 
deionised water. 300 ul of reagents containing H2O2 is injected into the cuvette 
containing the reaction mixture to trigger the chemiluminescent reaction (the amount 
of light emitted during oxidation of acridin丨画 ester in the cuvette is measured). 
A direct relationship exists between the TSH in a sample and the relative light units 
(RLUs) detected by the instrument (Corning ACS 180). 
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a s s a y F o r m 
Amerlex-M Free T3 RIA kit from Kodak Clinical Diagnostics Ltd. (Amersham, UK) 
was used for assay ofFT3. The kit utilizes a radioactive tracer, a high specific activity 
I 
；125I]-triiodothyronine derivative which has been chemically modified to inhibit its 
binding to the endogenous T3 binding proteins but which binds normally to antibodies 
to T3. When this radioactive tracer is mixed with a serum sample and a specific high 
affinity T3 antibody, an equilibrium is established in which the free T3 and the [1251 - ‘ 
triodothyronine derivative compete for a limited number of binding sites on the 
antibody (see fig 12). The design of the assay with the use of a limited amount of 
antiserum has ensured that the disturbance of this T3/binding protein equilibrium is 
minimized. The proportion of [125I]-triodothyronine derivative bound to the T3 
antibody is inversely related to the concentration of the free T3 present in the serum. 
The Amerlex-M antibody suspension contains antibody that is bound to magnetisable 
polymer particles. Separation of the antibody- bound fraction is effected by magnetic 
attraction of the Amerlex- M suspension and decantation of the supernatant. By 
measuring the proportion of [125I]-triodothyronine derivative bound in the presence 
of reference standard sera the concentration of free T3 present in unknown samples 





Fig 12 : Principle of direct FT3 RIA. 
(copied from manual for Ainerlex-M Free T3 RIA kit, Kodak Clinical 
Diagnostics) 
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In the assay,"Ligand A,B and C", preparations supplied from Ciba Coming 
Diagnostic, and containing constituents commonly assayed by radioimmunoassay, 
were used as controls. These control sera are prepared from human semm. No 
preservative or stabilizers have been added. 
Radioactivity was measured on a Cobra Auto-Gamma 5010 counter and results were 




ASSAY FOR FT4 
The Ciba Coming ACS FT4 assay is a competitive immunoassay. FT4 in the sample 
competes with acridinium ester (AE)-labeled T4 (Lite Reagent) for a limited amount 
of polyclonal rabbit anti-T4 antibody, which is covalently coupled to paramagnetic 
particles (Solid Phase). 
100 ul of Lite Reagent and 450 ul of solid phase is added to 25 ul of sample and 
incubated at 37 C for 7.5 minutes. Solid particles are separated from the mixture by 
magnetism and aspiration of aqueous phase. Solid particles are then washed by 
deionised water. 300 ul of reagents containing H2O2 is injected into a cuvette 
containing the reaction mixture to trigger the chemiluminescent reaction (the amount 
of light emitted during oxidation of acridinium ester in the cuvette is measured). 
An indirect relationship exists between the FT4 in a sample and the relative light units 
(RLUs) detected by the instrument (Coming ACS: 180). 
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RELATIONSHIP BETWEEN LAP SCORE AND LEUCOCYTE A L K A L I N E 
PHOSPHATASE (SA-LALP、 
The first question being asked was the extent to which the semiquantitative LAP score 
and SA-LALP were associated. Figure 1 shows the relationship. A statistically 
I 
significant direct correlation was found (r=0.57; P,0.001; df^61). The relationship held 
true when examined by patient diagnosis except for the hypothyroid group. 
Correlation between LAP score and SA-LALP 
n r P 
all subjects 62 0.57 <0.001 
control subjects 19 0.76 <0.001 
"normal" patients 19 0.61 <0.05 
"hypo" patients 9 0.27 0.76 
"hyper" patients 14 0.51 0.06 — 
The relatively high correlation between these variables is not surprising since the same 
activity is being assessed. One method uses a visual assessment while the other is 
quantitative. 
This project was an attempt to use SA-LALP as a cellular marker for thyroid status, 
and measurement of specific activity (amount of enzyme activity per unit amount of 
protein), therefore, was expected to be a superior approach. 
The correlation between LAP score and SA-LALP for "Hypothyroidism" patients is 
. ... --- .--- .:...- -.-
—-——.—=— 9 3 
dna 
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Pig 1: Relationship between LAP score and Specific Activity of 
Leucocytic Alkaline Phosphatase (SA-LALP): 
Each. point represents one case. 
All cases are include:i. 
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appreciately lower than for the other subgroups. Case 51 (see Appendix I I ) is an 
outlier. The value of SP-LALP (2.43 mU/mg.), is only about 1/6 of the mean value of 
this subgroup (15.1 mU/mg.), while the LAP score (134) is very close to the mean 
(155) of this subgroup. The explanation might lie in an analytical error in one or 
other, or both methods. , 
[Table-1]: Mean values of LAP score and SA-LALP for each diagnostic subgroup. ‘ 
mean LAP score mean SA-LALP (mU/mg) 
all subjects 83 8.52 
control subjects 64 7.72 
"normal" patients 76 7.81 
"hypo" patients 155 15.1 





I t should be noted that those diagnostic groups were as given by the requesting 
doctors, modified in three cases by the new results. It is well known that there is 
ambiguity in the clinical diagnosis of thyroid status [177]. Often the results of 
laboratory tests, do not match the clinical diagnosis. Furthermore, knowledge of 
previous results could well have influenced clinical assessment. The picture is further 
complicated by the fact that most patients were not new cases to the thyroid clinics. 
They had mostly been treated by means such as T4 replacement therapy, iodine 
treatment, thyroidectomy, antithyroidal drugs etc. It should be noted that the « 
classification is based mainly on the clinical assessment. 
In much of the data analysis that follows, the intrepretation is based mainly on the 
statistics calculated from all cases. A separate section on the diagnosis of 
hypothyroidism is made in order to highlight the complexity of assessing thyroid 
status. Hypothyroidism is the group chosen since it has the greatest potential to 
reflect the usefulness ofSA-LALP, as can be seen later in this chapter. 
From Table 1，it can be seen that LAP, score values were in general much higher for 
hypothyroid patients than for those of 丨normal, and hyperthyroid patients. This 
outcome confirms the work of Refetoff<6>, who demonstrated that L A P activity is 
‘usually elfevated in hypothyroidism. More detailed analysis of the LAP score and SA-
LALP with respect to TSH results wil l be given below. 
% 
. . . - - - — • -
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DIAGNOSIS OF HYPQTHYROTDTSM I N R E L A T I O N TO TSH A N D FT4 
Accurate and efficient diagnosis of hypothyroidism requires awareness of the clinical 
features that define a patient's risk of thyroid hormone deficiency and proper use of 
two tests to confirm the disorder, viz the serum TSH and free thyroxine (T4) 
concentrations. These sensitive measures of thyroid function have largely resolved the 
inaccuracy associated with the clinical diagnosis of hypothyroidism, but they have also 
revealed frequent thyroid test abnormalities in sick patients without actual thyroid 
dysfunction [167]. 
Three classes of clinical manifestation suggest possible hypothyroidism: (1) symptoms 
and signs of thyroid hormone deficiency; (2) evidence of disease, previous treatment, 
or exposure known to cause thyroid gland or pituitary thyrotroph failure; and (3) 
presence of disorders associated with increased risk of autoimmune thyroiditis. 
Laboratory testing should follow clinical suspicion raised by the above manifestations. 
....Failure of thyroid" hormone production caus终 a decline in circulating thyroid hormone 
• concentrations and, in primary hypothyroidism, reduces inhibition of pituitary TSH 
production. In most overtly hypothyroid patients, low serum T4 and high serum TSH 
concentrations confirm the diagnosis, whereas the infrequent cases of central 
hypothyroidism have hypothyroxinemia accompanied by a low or normal serum TSH — 
level. This general rule has two limitations: (1) altered levels of T4 binding to serum 
proteins may falsely suggest or mask hypothyroidism, and (2) with mild thyroid 
dysfunction, the serum TSH level may be elevated despite a normal serum T4 
concentration. 




in symptomatic patients. In fact, when patients screened for potential TBG 
derangements (eg, oral contraceptive use and pregnancy) are excluded, the sensitivity 
of the serum total T4 assay for this diagnosis is greater than 90% [168]. 
Serum TSH measurements are an exquisitely sensitive way of identifying virtually all 
patients with any degree of primary hypothyroidism. As thyroid hormone production 
decreases in the most common forms of gland failure (ie，autoimmune thyroiditis and 
post-ablative hypothyroidism), serum TSH typically rises even before the serum T4 
becomes subnormal. Because an elevated serum TSH level identifies primary 
hypothyroidism, the analytic sensitivity of TSH assays (ie, the least detectable TSH 
concentration) is not a critical issue. 
The combination of an elevated serum TSH with a normal free T4 concentration has 
been termed subclinical hypothyroidism. These findings are present in some 
apparently healthy people [169], particularly elderly women. 
Serum TSH measurements alone are not a perfect approach to identify all patients 
with hypothyroidism [170]. Patients with central hypothyroidism typically have low or 
. normal serum TSH--levels. Furthermore, serum TSH" concentrations may be 
inappropriately elevated with respect to circulating thyroid hormone concentrations in 
several unusual conditions [174] _ generalized thyroid hormone resistance and TSH-
mediated hyperthyroidism - but this combination o f results is most commonly due to 
intermittent noncompliance in treated hypothyroid patients. Semm-- TSH 
concentrations also are transiently elevated during recovery from nonthyroidal illness 
[175]. 
Serum TSH concentrations are often subnormal in patients with nonthyroidal illness 
[176], but low TSH secretion seldom, i f ever, masks significant primary 
hypothyroidism. Differentiating the hypothyroxinemia requires careful consideration 
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of clinical and laboratory evidence suggesting hypothalamic or pituitary disease (eg, 
atrophic testes in men or lack of elevated serum follicle-stimulating hormone 
concentrations in postmenopausal women). 
I 
I 
_ _ 、、 
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RELATIONSHIP BETWEEN SA-LALP, TSH AND FT4 
To explore the relationship between SA-LALP and thyroid status of patients, the 
most useful approach would seem to be to look at TSH values. Although TSH does 
not serve as a 'gold standard' for thyroid status (discussed in previous section), it is a 
sensitive way of identifying most patients with any degree of primary hypothyroidism, 
and it typically rises even before the semm T4 becomes subnormal. . 
I 
[Table-2]: Mean values of SA-LALP, TSH, and FT4 of each subgroup. 
mean SA-LALP mean TSH mean FT4 
mU/mg mlU/L pmol/L 
all subjects 8.52 9.43 28.5 
control subjects 7.72 1.65 17.38 
•normal' patients 7.80 2.42 19.50 
•hypo, patients 15.10 42.2 15.66 
•hyper' patients 5.10 0.04 65.7 
Table 2 indicates that, for normal patients and control subjects, the average TSH 
:va lues lie within the normal reference mterval of 0.3 to 4.0 mlU/L. Hypothyroid 
patients had a mean TSH level well above 4.0 mlU/L. For older patients, the cut of f 
point for defining hypothyroidism may well be higher (TSH>= 10 mlU/L is very 
often used clinically). Hyperthyroid patients had a mean TSH level well below 0.3 
mlU/L. Since the detection limit of our method for TSH is 0.03 mlU/L, values less 
than 0.03 mlU/L were taken as 0.03 mlU/L in the data analysis. The true mean value 




FT4 was measured in conjunction with TSH in order to validate the diagnosis of 
hypothyroidism (refer to Appendix II). From Table 2, it can be seen that hypothyroid 
patients had average FT4 results (15.66 pmol/L) less than that of control 
subjects(17.38 pmol/L) and "normal" patients (19.50 pmol/L). For hyperthyroid 
patients, the average FT4 (65.7 pmol/L) is much higher than for the normal group. 
Since most patients had been treated for their thyroidal diseases (for example, T4 
replacement, iodine treatment，antithyroidal drugs etc.), the FT4 values are likely to 
unreliable in indicating the status o f the thyroid gland. 
A plot for SA-LALP against FT4 values is is shown in fig 2. It can be seen that for 
those patients with a high level of FT4 (ie, most likely to be hyperthyroid, except for 
one case, SA-LALP tends to be confined to a value less than about 8 mU/mg. This 
observation is similar to that of the low TSH results, or high FT3 results, as can be 
seen later. Unfortunately, many results from other patient groups have similar values 
of SA-LALP, thus reducing the value of SA-LALP and FT4 as a useful guide for 
hyperthyroidism. 
A plot of LAP score against FT4 is shown in: f ig 3. Bearing in mind the strong 
association link between LAP score and SA-LALP values, the great similarity in the 
pattern of the two plots is not surprising. Again, for those patients with high FT4 
results, the LAP score tends to be below 100. 
— * 
A quite specific pattern of results is found for values of SA-LALP for different 
thyroid status groups. Hypothyroid patients had average results (15.1 mU/mg) 
significantly different from those of control subjects (7.7 mU/mg) and」normai_ 
patients (7.8 mU/mg). The average results for hyperthyroid patients were not so 
greatly different from controls (5.1 mU/mg as against 7.7 mU/mg). Student t-test, 
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significantly different from that of the control and 'normal' patient groups (P<0.05). 
The hypothyroid group differed very significantly from that of the control and 'normal' 
patient groups (P<0.01). 
The overall impression is that SA-LALP rises in hypothyroidism but has an unclear 






Table 3 shows the correlation between TSH with that of SA-LALP and LAP score 
values. Since the values for TSH show a highly skewed distribution, the correlations 
were calculated taking the natural logarithms of the TSH results. 
I 
[Table 3]: Correlations between TSH and SA-LALP,TSH and LAP score 
SA-LALP LAP 
n r r 
•normal'patients 19 0.57{P<0.01) 0.40(P=0.09) 
•hypo' patients 9 0.67(P=0.02) 0.49(P=0.10) 
•hyper' patients 14 -0.19(P二0.51) -0.01(P=0.96) • 
I t can be seen that a significant correlation exists between SA-LALP and TSH，LAP 
and TSH for normal and hypothyroid patient groups. The poor correlation for 
hyperthyroid patients groups may be partly due to clustering of TSH results at the 
lower detection limit of 0.03 mlU/L. 
r 
Such a relation can best be investigated by putting all those points into a single plot. 
This wi l l be done in a separate section. 




R E L A T I O N S H I P B E T W E E N FT3 AND O T H E R RESULTS 
The original purpose of assaying FT3 in this project was to help diagnose 
hyperthyroidism in conjunction with TSH measurement. The reference interval for 
FT3 is 3.3-8.2 pmol/L. Since the distribution of FT3 level was skewed, a 
transformation to logio logarithms was made. 
I 
[Table-4] The mean levels o f log io [FT3] for different patient groups. 
mean SD calculated 95% 
confidence 
intervals (antilog values) 
(pmol/L) 
all subjects 0.843 6.52 2.12 -22.85 
control subjects 0.765 0.118 3.38 - 10.02 
•normal' patients 0.777 (5.163 . 2.82 - 12.67 . 
• 'hypo' patients 0.587 • 0.169 1 .77-8 .41 
•hyper'patients 1.178 0.243 4.92-14.58 
The results showed very high values for hyperthyroid patients. Although there was 
overlap of levels for different groups, the FT3 results agreed with what we should 




-The plot of values for SA-LALP against FT3 results is shown in fig 4. High FT3 
values (mainly in the clinically hyperthyroid patient group ) are associated wi th SA-
！ 
LALP less than 10 mU/mg with the outlier excluded. There is no statistically 
significant association between SA-LALP and FT3 in the other groups. Again, this is 
I 
not surprising given the clustering of values over a narrow range. 
Fig 4: Relationship between specific activity andFT3. 
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Table 4.1 shows the relationship between SA-LALP and FT3 for different patient 
subgroups. Since the FT3 values were skewed, the correlations were calculated by 
taking the log 1 0 logarithm of FT3 and SA-LALP results. 
J 
[Table 4.1]: Correlation coefficients between log(SA-LALP) and log(FT3) -
n 
subjects 57 -0.46(P<0.01) 
control subjects 19 -0.39(P=0.09) 
•normal' patients 19 -0.40(P二0.08) 
•hypo' patients 7 -0.53(P=0.21) 
•hyper' patients 12 -0.14(P=0.63) 
The correlation coefficients are statistically significant only when all subjects 






R E L A T I O N S H I P B E T W E E N SA-LALP AND T S H 
The SA-LALP of 19 control subjects, 19 "normal" patients, 9 hypothyroid patients 
and 14 thyrotoxic patients were plotted against their'log-transformed TSH results (fig 
5). The vertical lines represent TSH 二 0.3 and 4.0 mlU/L, the lower and upper limits 
of the normal reference interval for TSH. The criterion of TSH > 4.0 mlU/L is not 
definitive for the diagnosis of hypothyroidism. For older people, the value can be 
higher (TSH > 10 mlU/L). 
Eight out of nine hypothyroid patients exhibited SA-LALP above 10 mU/L. Two of 
the control subjects and three patients who had been treated and defined as euthyroid 
also had SA-LALP above 10 mU/L. There was no clear differentiation of SA-LALP 
between the normal patients and hyperthyroid patients, although the mean of SA-
LALP was 7.81+4.31 mU/L and 5.10±4.07 mU/L respectively for the two groups. 
The results suggest that SA-LALP is not sensitive enough to differentiate between 
normal and hyperthyroid subjects. 
On the other hand, the trend towards a significantly higher SA-LALP for hypothyroid 
cases is obvious. Because of the overlap between diagnostic groups, a means of 
expressing the diagnostic usefulness of the SA-LALP at differing values was sought. 
There is no definitive diagnostic test for thyroid status, but the TSH level seemed to 





Fitr 5： The values of SA-LALP are plotted as a function of TSH (x-axis 
。 transformed to iogio logorithms). The normal reference interval. 
of TSH is represented by two vertical lines. 
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ROC PLOTS, DISTRIBUTION OF SA-LALP AND LAP VALUES 
The clinical performance of a laboratory test can be described in terms of diagnostic 
accuracy, or the ability to correctly classify subjects into clinically relevant subgroups. 
Diagnostic accuracy refers to the quality of the information provided by the 
classification device and should be distinguished from the usefulness, or actual 
practical value, or the information. Receiver-operator characteristic (ROC) plots 
t 
provide an index of accuracy by demonstrating the limits of a test's ability to ‘ 
discriminate between alternative states of health over the complete spectrum of 
operating conditions. Furthermore, ROC plots occupy a central or unifying position 
on the process of assessing and using diagnostic tools. 
Details and theory of ROC plots will not be discussed in this thesis. However, several 
terms are essential for discussing ROC plots [173_. 
SENSITIVITY is used to characterize the incidence of true-positive results obtained 
when a test is applied to patients known to have the disease. 
SPECIFICITY is used to characterize the incidence of true-negative results obtained 
when a test is appled to subjects known to be free of the disease. 
PREDICTIVE VALUE of a positive test result is defined as the percentage of 
\ 
positive results that are true positives when the test is applied to a population 
containing both healthy and diseased subjects. 
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TRUE POSITIVES: number of sick subjects correctly classified by the test. 
FALSE POSITIVES: number of healthy subjects misclassified by the test. 
TRUE NEGATIVES: number of healthy subjects correctly classified by the test. 
FALSE NEGATIVES: number of sick subjects misclassified by the tests. 
I 
V 
• • _ •. . . . 一 . . 
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A plot (fig-7) is constructed from calculated sensitivity and specificity listed at Table 
6. 
Intrepretation of the ROC plot: 
The ROC graph is a plot of all of the sensitivity/specificity pairs resulting from 
I 
continuously varying the decision threshold over the entire range of results observed. 
In each case, the ROC plot depicts the overlap between the two distributions by 
plotting the sensitivity vs 1 - specificity for the complete range of decision thresholds. 
On the y-'axis is sensitivity, or the true-positive fraction. It is calculated from the 
affected subgroup (as defined by a TSH value >=4 or >=10 mlU/L). On the x-axis is 
the false-positive fraction, or 1 - specificity. It is an index of specificity and is 
calculated from the unaffected subgroup (in this case subjects with TSH value〉=4 or 
>=10 mlU/L). Because the true- and false-positive fractions are calculated entirely 
separately, by using the test results from two different subgroups, the ROC plot is 
independent of the prevalence of disease in the sample. 
A test with perfect discrimination (no overlap in the two distributions of results) has 
an ROC plot that passes through the upper left comer, where the true-positive 
fraction is 1.0，or 100% (perfect sensitivity), and the false-positive fraction is 0 
(perfect specificity). The theoretical plot for a test with no discrimination (identical 
distributions of results for the two groups) is a 45o diagonal. Qualitatively, the closer 




[Table 6]: Calculated sensitivity, specificity and predictive values for SA-LALP and 
LAP score in detecting TSH values greater than a certain cut off level. 
Units of TSH and Specific Activity of Leucocytic Alkaline Phosphatase were mlU/L 
and mU/mg respectively. LAP stands for LAP score. SP-LALP stands for specific 
activity of Leucocytic Alkaline Phosphatase. 
Sensitivity is calculated as TP/(TP+FN) 
I 
Specificity is calculated as TN/(TN+FP) 
Predictive value of a positive result is calculated as TP/(TP+FP) 
TP = True Positive 
FP = False Positive 
TN = True negative 
FN = False negative 
TSH >4.0 
sensitivity specificity 1-specificity predictive 
value -
SA-LALP>2 100 10 90 21 
>4 91.6 26 74 22.9 
>8 91.6 74 26 42.3 
>10 91.6 90 10 68 
>15 66.6 94 6 72 
>20 . 41.6 100 0 100 
TSH〉10.0 
SA-LALP >2 100 9.1 90.9 12.2 
>4 100 25.4 74.6 14.5 
>8 100 69 31 39.2 
>10 100 83.9 16.4 43.2 
>15 57.1 87.2 11.8 46.3 
>20 57.1 98.1 1.9 80 
TSH〉10.0 
LAPscore>30 100 21.8 78.2 13.4 
>60 100 45.8 54.6 18.9 
>90 71.4 70.9 19.1 23.8 
>150 28.5 94.5 5.5 40 
>200 28.5 94.5 5.2 66.6 
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d e t e c t i n g a cut off value- of TSH> = 4 m l U / L ; Solid s q u a r e ( P 
) i s the plot of s e n s i t i v i t y against l - s p e c i f i c i t y of SA-
、，LALP i n d e t e c t i n g a c u t o f f v a l u e of TSH〉=10 m l U / L . 
1 0 9 - b 
Chap 4 
Due to the limited number of specimens assayed, the ROC plot so generated does not 
appear as a very smooth curve. The non-diagonal nature as well as proximity to the 
upper left comer shows that both LAP score and SA-LALP are reasonably good tests 
of discrimination with respect to TSH level. The SA-LALP curves lies closer to the 
upper and left corner, indicating that it has higher overall usefulness than the LAP 
• I 
score. 
SA-LALP (refer to Table 6) shows superiority in sensitivity over that of LAP score. 
I 
The former, at the 50th percentile of its own distribution (see fig 8.1 as well), is able 
to catch over 90% of 'hypothyroidal丨 TSH values (>=4mIU/L) defined from 
laboratory 'point of view' (i.e. a sensitivity of 90%). LAP score, however, at 50th 
percentile of its own distribution (see fig 8.2 as well), catches only about 70% of 
those data, even if the cut off point for TSH is set a t � 二 10 mlU/L. If the cut off point 
for TSH is set at >=10mrU/L, SA-LALP is able to catch 100% of all cases at 50th 
percentile of its own distribution. 
’、 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































[Table-8]: table showing the characteristic of the distributions of SA-LALP, LAP and 
TSH, FT3 and FT4. 
Mean SD Min Max. Range Skewness 
I 
SA-LALP 8.52 6.15 0.92 27.7 26.8 1.22 
LAP 82 63.3 15 . 340 325 8.7 . 
TSH 9.43 6.52 0.03 164 163.9 4.08 
logTSH -0.17 1.08 -0.15 2.22 3.73 0.168 ‘ 
FT3 8.51 6.52 2.30 29.30 27.0 5.76 
FT4 28.51 27.12 4.11 143.1 138.9 8.74 
The distribution of SA-LALP (fig-8.1) and LAP score are skewed (fig 8.2). For TSH, 
the range is very large. For analytical purposes, a logio logorithm transformation was 
made (fig 8.3). 
The ROC curves above are functions of the TSH criterion. The main point to be made 
is that using the same criterion for diagnosing hypothyroidism the ROC curve for SA-
LALP is more useful than the one for LAP score. 




The predictive value of a certain test in defining a certain diagnosis depends upon the 
prevalence of the conditon. In this case, the predictive values apply to a thyroid clinic 
population rather than the general population. I f TSH>=10.0 mJU/L is taken as the 
cut of f point, a predictive value of only 43% is achieved at a level of SA-LALP=10 
I 
mU/mg., which corresponds to about the 70th percentile of the SA-LALP I f the 
criterion for labelling a patient as hypothyroid by TSH results is lowered to that 
TSH>=4 mlU/L, a SP-LALP value =15 mU/mg, which corresponds to about the 80th 
percentile of its distribution, gives a predictive value of 72% (because the prevalence ‘ 
increases). In the clinical setting, a value of TSH >4mIU/L alone is too liberal in 
making a diagnosis of hypothyroidism. Nevertheless, SP-LALP is potentially a tool 
for assisting in the diagnosis of hypothyroidism. 
The distribution of SA-LALP results is positiv^y skewed (fig 8.1). Since the samples 
were taken from clinically thyroid patients, such a distribution can not be taken as 
representing that of the general population. Due to the limited number of samples 
assayed，the suggestion from the histogram that the distribution has multiple modes 
may be incorrect. 






CHAPTER 5: DISCUSSION 
I 
i 
LIMITATIONS OF CURRENT THYROID FUNCTION TESTS FOR THE 
ASSESSMENT OF TISSUE RESPONSE TO VARYING LEVELS OF 
THYROID HORMONES 
PROBABLE RELATIONSHIP BETWEEN ALKALINE PHOSPHATASE 
ACTIVITY IN LEUCOCYTES AND THYROID STATUS AT CELLULAR 
LEVEL 
SPECIFIC ACTIVITY OF LEUCOCYTE ALKAL INE PHOSPHATASE AS A 




LIMITATIONS OF CURRENT THYROID FUNCTION TESTS FOR THE 
ASSESSMENT OF TISSUE RESPONSE TO VARYING LEVEL OF THYROID 
HORMONES 
I 
There have been important changes in the technology of thyroid function testing over 
tht last ten years. Most notably, thyrotropin (TSH) assays of greater sensitivity have 
come into general use, so that it is now possible to make a reliable distinction between 
normal and low semm TSH values. There also has been a proliferation of assays for 
serum free thyroxine (FT4) and triiodothyronine (FT3), with a tendency for these to 
replace the dual measurements of total hormone and an index of binding. 
I f a sensitive serum TSH assay is used together with a valid serum free T4 estimate, 
an assessment of thyroid status can be made from the general relation between tropic 
and target hormones. Those levels can distinguish between : (A) Primary target gland 
failure - high tropin, low product, (B) Tropic failure - both low, (C) Autonomous or 
abnormally stimulated target gland function - high product, low tropin, (D) Primary 
excess of tropic hormone or hormone resistance _ both high. 
Although the above scheme seems to allow precise diagnosis of thyroid dysfunction 
to be made from a single seurm sample, it depends on several assumptions: 
: Firstly, the sample is taken- in steady-state conditions: Common deviations from the 
steady state relate to spontaneous fluctuations in hormone secretion, as well as to 
therapeutic responses and the spontaneous evolution of disease. In considering such 
discrepancies, it is worth noting that serum TSH has a considerably shorter half-life 
than either T3 or T4 and tends to deviate more rapidly from the steady state. 
Secondly, the active hormone concentration has been accurately measured: Free 
114 
Chap 5 
hormone estimates are susceptible to error, and may fail to demonstrate the effect o f 
circulating inhibitors of binding. Available TSH and iodothyronine assays make 
comparative, rather than absolute, measurements of hormone concentrations, based 
on the assumption that the serum sample and the assay standard differ only in their 
concentration of analyte. Any other difference between the sample and the standard, 
» 
however, may influence the assay signal, as for example, with abnormal binding of the 
tracer, as well as possible nonspecific interference with enzymatic, fluorescent, or 
chemiluminescent detection systems. The relation also may be misleading I f 
immunoreactive TSH of reduced biologic activity is secreted. , 
Thirdly, the tissue responses are proportional to the active hormone concentration: In 
most patients, there is a close correlation between the active hormone concentration 
and clinical features, but in generalized thyroid hormone resistance (although 
extremely low in incidence), high serum levels of free T4 and T3 are required to 
maintain the euthyroid state. In the absence of sensitive, specific indices of thyroid 
hormone action in tissues other than the pituitary, clinical assessment is crucial in 
assessing the effect of thyroid hormone excess or deficiency. The onset and offset of 
thyroid hormone action is slow, so that tissue responses may lag behind changes in the 
active hormone level in serum. Moreover, some medications (eg, amiodarone [58] 
and phenytoin"[55]) also appear to modify the peripheral expression of thyroid 
hormone action. 
Fourthly, normal reference ranges apply to the healthy study subjects: Age-related 
variations [188], associated illness，nutritional changes, pregnancy and various 
medications may cause aSsay results to fall outside normal reference ranges defined in 
healthy subjects. 
I t can be seen that there is no "gold standard" for defining thyroid status of a patient. 
Moreover, whether a person has disease or not should be understood as his or her 
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body status deviates from that of "normal". Some sort of index, whether it is at the 
level o f tissue, cellular or molecular level, would be useful in defining the actual 
influence of thyroid hormone excess or deficiency. I f clinical assessment can be 
regarded as qualitative measurement of tissue response to thyroid status, the quantity 
of certain substances within certain cell groups can might regarded as cellular markers 
I 
for thyroid dysfunction i f statistically significant relationships are found between them. 
In the clinical setting, the tissue responses rather than the absolute level of thyroid 
hormones are of greater concern, as those responses are the actual clinical 
manifestations which differentiate normal from pathological states. 
The potential of using cellular markers in defining pathological thyroid states is 
enormous. Although the underlying mechanisms of their changes in relation to varying 
thyroid status are largely uncertain at present, they wil l be, i f discovered, free from 
some limitations for serum levels of free T3，free T4 and TSH. They wi l l be 
independent of the feed-back system between the tropin and the product, therefore 
avoiding discrepancies occuring in the early phases of treatment for both 
hyperthyroidism and hypothyroidism and during recovery from the hypothyroxinemia 
of severe illness. Tissue responses can be regarded in concept as summation of 
cellular responses. I f the influence of thyroid hormones is assessed at the cellular 
level, theoretically it should provide a better indication of tissue response than merely 






PROBABLE RELATIONSHIP BETWEEN ALKALINE PHOSPHATASE 
ACTIV ITY WITHTN LEUCOCYTES AND THYROID STATUS OF PATIENTS 
AT THE CELLULAR LEVEL 
I 
Alkaline phosphatase is a dimeric moleocule of about 160,000 molecular weight 
189]. The two subunits interact with negative co-operativity and consequently the 
enzyme shows "half of the sites" reactivity at physiological pH [190], but displays 
Michaelis kinetics at alkaline pH (above 9). Each subunit contains a tightly-bound 
atom of zinc which is essential for the structural integrity of the enzyme and a second, 
less tightly-bound zinc atom which is involved in the catalytic process [191]. Alkaline 
phosphatase activity is stimulated by magnesium ions [192]. This ion binds to an 
effector site on each subunit which is different from the site for zinc. The magnesium 
ion exerts an allosteric effect on the enzyme to stimulate the dephosphorylation 
process. Zinc ions can also bind to the magnesium site with greater affinity than the 
magnesium itself, resulting in a loss of activity. 
Although the idea of measuring alkaline phosphatase activity within leucocytes was 
inspired from literature [178,179] which related high LAP score to hypothyroidism, a 
possible relationship between cellular zinc level and alkaline phosphatase is worth 
mentioning. Red cell zinc level decreases in hyperthyroidism but is normal in 
hypothyroidism [180]. Since alkaline phosphatase activity is so closely related to 
zinc, some relationship may exist between leucocyte zinc level and specific activity of 
leucocyte alkaline phosphatase. 
... 
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SPECIFIC ACTIVTTY OF T^FTTPQCYTE ALKALINE PHOSPHATASE AS A 
POTENTIAL CELLULAR MARKER FOR HYPOTHYROIDISM 
Specific activity of leucocyte alkaline phosphatase (SA-LALP) was measured in 
patients of different thyroid status. The data presented show that SA-LALP levels 
J 
and LAP score are elevated in patients with hypothyroidism. Levels of both were 
lower in hyperthyroidism, but were not statistically significantly different from those 
of euthyroid cases. 
I 
There is no single "gold standard" for defining hypothyroidism. If, however, a level of 
TSH>4.0mrU/L is used as a yardstick, level of SA-LALP〉10 mU/mg has a sensitiviy 
of over 90% in defining hypothyroid cases(table 6，chapter 4). I f TSH>10mIU/L is 
used as a critical level instead, a similar level of SA-LALP has 100% sensitivity for 
defining hypothyroidism. Of course, such high sensitivity should be understood in 
terms of the limited number of cases(n=62) studied, and the limitation of TSH as a 
single entity to represent thyroid status of patients. Sensitivity alone is insufficient to 
represent the usefulness of a test. The predictive value, that is, the probability that a 
patient with a positive or negative test has, or does not have the disease depends upon 
the prevalence of the condition. In this study, the subjects for "hypothyroidism" were 
9 out of 62 cases. In the general population, the prevalence of thyroid diseases is 
estimated to be less than 5 %. The hypothyroid cases constitute only a minor 
proportion of this very low percentage. The predictive values of SA-LALP to define 
hypothyroidism in this study were representative—only of what might be seen in a 
thyroid clinic. Nevertheless,, those values provided some ideas to the potential 
usefulness the SA-LALP in defining hypothyroidism. In the study the predictive value 
of-SA-LALP〉10 mU/mg in defining a level of TSH greater than 4.0 mlU/L was 68%. 
Such predictive value is expected to be much lower for the general population since 
the prevalence of hypothyroid cases of which is much lower. 
- 、. 
. . - • • • 
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The potential of SA-LALP would likely improve i f neutrophils, rather the the gross 
leucocyte population were isolated for alkaline phosphatase assays. From experience 
in LAP score studies, it is a well known fact that alkaline phosphatase activity locates 
predominantly in neutrophils. Neutrophils constitute around 50 to 70% of leucocyte 
population for normal subjects. This proportion varies enormously between 
individuals and in different disease conditions. Such variation induces inaccuracy in 
the assessment of SA-LALP levels. The capability of the specific activity of neutrophil 
alkaline phosphatase to reflect peripheral tissue thyroid status is likely to be much 
I 
better than total leucocyte SA-LALP. I f this is found to be true, it may prove to be 
useful in patients in whom the serum TSH is not a reliable reflection of peripheral 
tissue thyroid status, such as secondary hypothyroidism, transient infantile 
hyperthyrotropinemia, and the syndrome of thyroid hormone resistance. 
The levels of LAP score for different thyroid patient groups in this study are similar to 
those given by that of RefetofF [181]. The LAP score's recognized characteristic as an 
acute phase reactant limits its clinical applicability. Elevations of LAP score are not 
=suf f ic ient ly specific for use in the diagnosis of hypothyroidism, since LAP score values 
are known to be elevated in many other situations [181], eg. metastatic malignancies 
. i •‘ 
[182], the post-operative period [183]，bacterial infections [184], pregnancy [185] , " 
oral contraceptive use [186], and during ovulation [187]. It is likely that levels of SA-
LALP share similar limitations. Nevertheless, SA-LALP shows superiority in 
discrimination of hypothyroidism over the LAP score, if TSH >4mIU/L to lOmlU/L is 
. u s e d arbitrary as a yardstick to define hypothyroidism, and further experience in the 
Chinese setting should show whether it adds anything to the presently available tests. 
Studies in subjects with secondary hypothyroidism, and in subjects with non-thyroidal 
illness but 'abnormal' thyroid function tests is worthwhile. Such studies should show 




CHAPTER 6 ： CONCLUSION 
I 
In this project, the quantitative method for meassuring SA-LALP did show an 
improvement over LAP score as a marker for hypothyroid status of patients. SA-
LALP has the potential for serving as a cellular marker for hypothyroidism i f the 
technique for measurement is more refined and more specifically, neutrophils rather 
than total leucocyte population be assessed for specific activity of alkaline 
phosphatase. 
The potential of using cellular markers in defining pathological thyroid status is 
enormous. Although the underlying mechanisms of their changes in relation to varying 
thyroid status are largely uncertain at present, they have the potential to be free from 
some limitations for serum level of FT3, FT4 and sTSH. They may be less dependent 
of feed-back system, therefore avoiding discrepencies occuring in the early phases of 
treatment for both hyperthyroidism and hypothyroidism and during revovery from the 
hypothyroxinemia of severe illness. 
« 
“ A P P E N D I X I 
S U M M A R Y OF PATIENT PARTICULARS 
CASE SEX/AGE HKID .NUMBER DIAGNOSIS 
1 F/54 D340560(6) NORMAL CONTROL 
I 
2 F £475505(5) NORMAL CONTROL 
3 F/54 B767559(9) NORMAL CONTROL 
4 F/27 C427523(l) NORMAL CONTROL 
5 M/54 'B557581(3) NORMAL CONTROL 
6 M/40 E438783(3) NORMAL CONTROL 
7 M/52 A170173(0) NORMAL CONTROL 
8 F/50 A740953(5) NORMAL CONTROL 
9 M/24 G681773(3) NORMAL CONTROL 
10 F/29 G114746(2) NORMAL CONTROL 
11 F/44 G235320(l) NORMAL CONTROL 
12 M/50 G235319(8) NORMAL CONTROL 
13 M/18 K314376(7) NORMAL CONTROL 
14 M/41 E531693(A) NORMAL CONTROL 
15 M B583635(8) NORMAL CONTROL 
16 F/43 A9469I2(8) NORMAL CONTROL 
17 F/32 E773215(9) NORMAL CONTROL 
18 M/53 B822001(3) NORMAL CONTROL 
19— F/32 G339660(5) NORAML CONTROL 
» 
20 F/54 B735488(l) EUTHYROID 
21 F/37 C556662(0) HYPOTHY. 
22 F/17 K482261(7) NON-EUTHYROID;TOXIC ON CME _ 
23 F/35 C400520(A) EUTHYROID; ON T4 
“ APPENDIX I 
24 F/43 E319880(8) EUTHYROID; TRANSIENT 
THYROIDITIS 
25 F/31 G557257(5) HYPOTHY.; ON T4 
26 F/23 D698551(4) HYPOTHY.;DRUG INDUCED 
27 F/41 £433547(7) EUTHYROID 
28 F/37 C556662(0) HYPOTHY.;ON T4 -
29 F/39 P074428(3) EUTHYROID; ON T4 
30 F/43 A894582(l) TOXIC; ON PTU 
31 M/25 D643315(5) EUTHYROID 
32 F/50 E983729(2) EUTHYROID 
33 F/48 B721881(3) TOXIC 
34 M/27 C508816(8) EUTHYROID;?T3 ANTIBODY 
35 F/58 B840382(7) TOXIC 
36 M/40 E777242(8) TOXIC 
37 F/77 A662577(3) SICK EUTHYROID 
38 F/44 B800860(A) EUTHYROID; ON T4 
39 F/43 E3 19880(8) EUTHYROID 
40 F/24 C505406(9) . EUTHYROID; PREGNANCY 
41 F/3-8 ' H362234(9) ？EUTHYROID;?MILD TOXIC 
42 F/28 C425436(6) EUTHYROID,? O ST 
THYROIDECTOMY 
43 F/23 0439122(4) 、TOXIC 
44 F/67 E03 5497(3) EUTHYROID 
45 F/70 G123 044(0) EUTHYROID; HYPO ON T4 
46 F/43 E3 19880(8) TOXIC; ON CME 
,47 F/64 ‘ B256031(9) TOXIC; POST ll31 
48 F/54 B958346(2) TOXIC 
- - . 
49 F/43 E3 90083 (9) TOXIC “ 
Page -2-
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50 F/22 G476839(5) TOXIC 
51 M B503432(4) HYPOTHY. 
52 F/61 B673686(l) EUTHYROID; POST 31 
53 F/63 C093790(6) HYPOTHY. 
54 F/32 £948369(5) HYPOTHY. 
55 F/28 C403787(A) TOXIC 
56 F/38 €248118(7) TOXIC . 
57 F/32 E759627(l) TOXIC 
58 F/48 K118985(9) HYPOTHY.; ON T4 
59 F/39 E3 81590(4) TOXIC 
60 F A860478(l) TOXIC 
61 F/33 C479388(7) HYPOTHY. 
62 F/77 B449523(9) EUTHYROID 
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It should be noted that the item DIAGNOSIS describes only the thyroid status of 
subjects or patients when the blood samples be taken. It may or may not represent the 
original thyroid problems that brought the patients to the thyroid clinics. 
J 
There were 9 male and 10 female subjects for acting as a normal control group. Age 
range for male subjects be 18-53 ( mean二40.2 ； SD二 14.4 ). Age range for female . 
subjects be 29-54 ( mean=40.5 ； SD=10.7). 
There were 4 male and 39 female patients included in the study. The predominance in 
number of female patients is not surprising as it reflects the difference of incidence 
between the two sex in general population. Age range for male patients be 25-40 , 
(mean=30,6). Age range for female patients be 17-77 (mean二42.7 ； SD=15.2). 
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APPENDIX I I 
S U M M A R Y OF PATIENT RESULTS 
CASE SA-LALP TSH FT3 LAP FT4 
SCORE 
(mU/mg) (mlU/L) (pmol/L) (pmol/L) 
I 
1 9.07 1.73 5.86 86 15.04 
2 7.70 2.74 5.27 53 14.22 
3 9.20 1.21 4.80 71 -- -
4 6.13 0.97 7.60 81 15.67 
5 • 1.60 2.90 5.77 35 20.12 , 
6 7.90 2.22 7.10 52 16.83 
7 18.40 1.08 5.70 124 19.82 
8 6.35 0.88 6.30 4 7 16.25 
9 15.34 2.40 2.80 101 16.76 
10 5.70 1.71 3.30 28 17.67 
11 2.17 1.78 6.30 43 17.22 
12 8.50 0.64 7.70 66 21.14 
13 8.80 0.98 5.20 54 19.67 
14 5.70 1.64 7.50 86 16.87 
15 6.90 1.17 6.40 43 18.83 
16 4.80 1.85 6.80 72 16.03 
17 9.87 1.71 5.30 79 14.96 
18 6.40 1.10 6.60 35 15.72 
19 6.30 2.69 7.70 63 20.02 
2 0 4.35 0.03 5.20 79 16.45 
2 1 14.60 120.00 2.30 3 4 0 4.11 
2 2 7.90 1.10 6.40 99 20.60 ‘ 
23 - 1.98 0.03 6.10 25 ‘ 25.61 
24 5.00 0.05 14.70 17 20.10 
25 12.30 46.80 4.20 140 13.80 
26 20.60 7.23 5.30 3 2 2 8.39 
27 6.70 1.25 4.60 17 16.41 
28 21.80 75.91 2.80 135 18.24 
2 9 4.80 2.52 5.20 43 --
30 5.10 0.03 7.40 98 35.19 
31 7.51 2.87 5.90 121 14.36 
3 2 11.20 20.51 3.90 83 10.74 
33 2.90 0.03 18.60 20 93.66 
3 4 5.67 2.28 6.30 95 — 14.34 
35 4.30 0.03 17.70 72 52.86 
36 6.06 0.03 27.60 61 73.82 
..37 8.34 0.74 3.20 53 13.46 
38 9.96 0.42 6.30 101 20.07 
A P P E N D I X I I 
CASE SA-LALP TSH FT3 LAP FT4 
SCORE “ 
(mU/mg) (mlU/L) (pmol/L) (pmol/L) 
39 16.30 0.03 29.30 70 103.06 
40 8.70 0.64 5.00 20 15.05 
41 3.14 0.03 15.40 ‘ 15 38.97 
42 15.10 5.52 6.10 198 15.05 
43 4.86 0.03 24.70 98 98.11 
44 6.28 1.27 5.70 121 23.54 
45 3.87 0.03 7.10 40 31.58 ' 
46 3.84 0.03 16.90 30 42.80 
47 19.50 6.76 5.30 101 10.50 , 
48 7.52 0.03 7.70 56 25.22 
49 2.38 0.03 13.50 22 54.59 
50 3.80 0.03 18.00 30 50.77 
51 2.43 4.89 6.40 134 13.57 
52 6.38 0.03 4.80 SO 25.94 
53 16.00 4.87 - 152 --
54 27.70 38.10 -- 87 --
55 10.10 0.03 6.40 70 16.21 
56 0.96 0.54 4.60 132 18.16 
57 0.97 0.03 28.70 20 143.08 
58 24.40 44.70 2.80 97 --
59 2.40 0.18 6.30 50 --
60 0.92 0.03 17.70 22 -
61 21.10 164.00 5.00 221 --
62 12.00 0.03 5.70 131 --
_ -
\ 
p a g e 一 2 -
A P P E N D I X I I 
S U M M A R Y OF RESULTS FOR CONTROL SUBJECT SUBGROUP 
CASE SA-LALP TSH FT3 LAP FT4 
SCORE 
(mU/mg) (mlU/L) (pmol/L) (pmoI/L) 
I 
1 9.07 1.73 5.86 86 15.04 
2 7.70 2.74 5.27 53 14.22 
3 9.20 1.21 4.SO 71 _ -
4 6.13 0.97 7.60 81 15.67 
5 1.60 2.90 5.77 35 20.12 , 
6 7.90 2.22 7.10 52 16.83 
7 18.40 1.08 5.70 124 19.82 
8 6.35 0.88 6.30 47 16.25 
9 15.34 2.40 2.80 101 16.76 
10 5.70 1.71 3.30 28 17.67 
11 2.17 1.78 6.30 43 17.22 
12 8.50 0.64 7.70 66 21.14 
13 8.80 0.98 5.20 54 19.67 
14 5.70 1.64 7.50 86 16.87 
15 6.90 1.17 6.40 43 18.83 
16 4.80 1.85 6.80 72 16.03 
17 9.87 1.71 5.30 79 14.96 
18 6.40 1.10 6.60 35 15.72 
19 6.30 2.69 7.70 63 20.02 
p a g e 一 3 -
A P P E N D I X I I 
S U M M A R Y OF RESULTS FOR " N O R M A L PATIENTS', SUBGROUP 
CASE SA-LALP TSH FT3 LAP FT4 
SCORE 
(mU/mg) (mlU/L) (pmol/L) (pmol/L) 
I 
20 4.35 0.03 5.20 79 16.45 
22 7.90 1.10 6.40 99 20.60 . 
23 1.98 0.03 6.10 25 25.61 
24 5.00 0.05 14.70 17 20.10 ' 
27 6.70 1.25 4.60 17 16.41 
29 4.80 2.52 5.20 43 18.24 
31 7.51 2.87 5.90 121 14.36 
32 11.20 20.51 3.90 83 10.74 
34 5.67 2.28 6.30 95 14.34 
37 8.34 0.74 3.20 53 13.46 
38 9.96 0.42 6.30 101 20.07 
40 8.70 0.64 5.00 20 15.05 
41 3.14 0.03 15.40 15 38.97 
42 15.10 5.52 6.10 198 15.05 
44 6.28 1.27 5.70 121 23.54 
45 3.87 0.03 7.10 40 31.58 
47 19.50 6.76 5.30 101 10.50 
52 6.38 0.03 4.80 80 25.98 
62 12.00 0.03 5.70 131 — 
. . ' • • 
p a g e 一 4 -
A P P E N D I X I I 
S U M M A R Y OF RESULTS OF CL IN ICAL HYPERTHYROID PATIENTS 
CASE SA-LALP TSH FT3 LAP FT4 
SCORE 
(mU/mg) (mlU/L) (pmol/L) (pmol/L) 
I 
30 5.10 <0.03 7.40 98 35.19 
33 2.90 <0.03 18.60 20 93.66 
35 4.30 <0.03 17.70 72 52.86 . 
36 6.06 <0.03 27.60 61 73.82 
39 16.30 , <0.03 29.30 70 103.06 
43 4.86 <0.03 24.70 98 98.11 
46 3.84 <0.03 19.60 30 42.80 
48 7.52 <0.03 7.70 56 25.22 
49 2.38 <0.03 13.50 22 54.59 
50 3.80 <0.03 18.00 30 50.77 
55 10.10 <0.03 6.40 70 16.21 
57 0.97 <0.03 28.70 20 143.08 
59 2.40 <0.18 6.30 50 --
60 0.92 <0.03 17.70 22 -
p a g e 一 6 -
f 
APPENDIX i n 
CONSENT FORM 
"Leucocyte Alkaline Phosphatase Activity in Thyroid Disease" 
Investigators: Mr Cheung Moon Wo, Dr AYW Chan, Prof JRL Masarei. 
f 
二 …：... (Chinese name: ) o f HKID no agree to 
participate in the above mentioned research study. The study,which involves 
venepuncture, has been explained to me to my satisfaction. I understand my right to 
withdraw from the study at any time. 
Signature of participant: 
V ‘ 
Date: 
司 意 書 
方 人 ^ _ ： ( X 文 姓 名 1 
I 4贫 f t 钱 h , % I I # 受 
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